

ENDORSED: 28 October 2021

doi:10.2903/j.efsa.2021.N.NNNN

1 **Scientific Opinion advising on the development of**
2 **harmonised mandatory front-of-pack nutrition labelling**
3 **and the setting of nutrient profiles for restricting nutrition**
4 **and health claims on foods**
5

6 EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA),
7 Dominique Turck, Torsten Bohn, Jacqueline Castenmiller, Stefaan de Henauw, Karen Ildico
8 Hirsch-Ernst, Helle Katrine Knutsen, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle,
9 Androniki Naska, Carmen Pelaez, Kristina Pentieva, Frank Thies, Sophia Tsabouri, Marco
10 Vinceti, Jean-Louis Bresson and Alfonso Siani

11 **Abstract**

12 Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and
13 Food Allergens (NDA) was asked to deliver an Opinion advising on the development of harmonised
14 mandatory front-of-pack nutrition labelling and the setting of nutrient profiles for restricting nutrition
15 and health claims on foods. This Opinion is based on systematic reviews and meta-analyses of human
16 studies on nutritionally adequate diets, data from the Global Burden of Disease framework, clinical
17 practice guidelines, previous EFSA opinions and the priorities set by EU Member States in the context
18 of their Food-Based Dietary Guidelines and associated nutrient/food intake recommendations. Relevant
19 publications have been retrieved through comprehensive searches in PubMed. The nutrients included
20 in the assessment have been selected based on expert knowledge. Food groups with important roles
21 in European diets have been considered. The Panel concludes that dietary intakes of SFAs, sodium and
22 added/free sugars are above current dietary recommendations and intakes of dietary fibre and
23 potassium are below current dietary recommendations in a majority of European populations. As excess
24 intakes of SFAs, sodium and added/free sugars and inadequate intakes of dietary fibre and potassium
25 are associated with adverse health effects, they could be included in nutrient profiling models. Energy
26 could be included in the model because a reduction in energy intake is of public health importance for
27 European populations. In food group/category-based nutrient profiling models, total fat could replace
28 energy owing to its high energy density in most food groups, while the energy density of food groups
29 with low or no fat content may be well accounted for by the inclusion of (added/free) sugars in the
30 model. Nutrients and non-nutrient components may be included in nutrient profiles for reasons other
31 than their public health importance to allow for a better discrimination of foods within the same food
32 category.

© 2021 European Food Safety Authority. *EFSA Journal* published by John Wiley and Sons Ltd on behalf of the European Food Safety Authority.

Keywords: diet, foods, nutrients, excess, inadequacy, diet-related chronic diseases

Requestor: European Commission

Question number: EFSA-Q-2021-00026

Correspondence: nda@efsa.europa.eu

Panel members: Dominique Turck, Torsten Bohn, Jacqueline Castenmiller, Stefaan De Henauw, Karen Ildico Hirsch-Ernst, Helle Katrine Knutsen, Alexandre Maciuk, Inge Mangelsdorf, Harry J McArdle, Androniki Naska, Carmen Pelaez, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsabouri and Marco Vinceti.

Acknowledgements: The Panel wishes to thank John Kearney for his contribution to this output and the protocol as member of the NDA Panel until June 2021.

ISSN: 1831-4732

© 20YY European Food Safety Authority. *EFSA Journal* published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

This is an open access article under the terms of the [Creative Commons Attribution-NoDerivs](#) License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.



The EFSA Journal is a publication of the European Food Safety Authority, an agency of the European Union.



35 Table of Contents

36	Abstract	1
37	1 Introduction	5
38	1.1 Background as provided by the mandate requestor	6
39	1.2 Terms of Reference as provided by the mandate requestor.....	8
40	1.3 Context of the assessment.....	9
41	1.4 Interpretation of the Terms of Reference.....	10
42	2 Data and Methodologies.....	10
43	2.1 Data.....	10
44	2.2 Methodologies.....	10
45	2.3 Definitions	11
46	3 Assessment.....	13
47	3.1 Nutrients and non-nutrient components of foods of public health importance for	
48	European populations.....	13
49	3.1.1 Nutrients and non-nutrient components of food for which intakes might exceed	
50	recommended levels in most population groups and countries in Europe.....	13
51	3.1.1.1 Energy.....	13
52	3.1.1.2 Fat	15
53	3.1.1.3 Saturated fatty acids	16
54	3.1.1.4 <i>Trans</i> fatty acids	17
55	3.1.1.5 Dietary sugars.....	18
56	3.1.1.6 Sodium.....	19
57	3.1.1.7 Conclusions.....	20
58	3.1.2 Nutrients and non-nutrient components of food for which intakes might be	
59	inadequate in relation to recommended levels in some population groups and	
60	countries in Europe	20
61	3.1.2.1 Protein.....	20
62	3.1.2.2 EPA and DHA	21
63	3.1.2.3 Dietary fibre.....	22
64	3.1.2.4 Potassium	24
65	3.1.2.5 Iodine.....	24
66	3.1.2.6 Iron.....	25
67	3.1.2.7 Calcium and vitamin D	26
68	3.1.2.8 Folate	28
69	3.1.2.9 Conclusions.....	28
70	3.2 Food groups which have important roles in diets of European populations and	
71	subgroups thereof.....	29
72	3.2.1 Role of food groups in European diets as addressed in food-based dietary	
73	guidelines of EU Member States.....	29
74	3.2.2 Food groups and health outcomes	31

75 3.2.3 Conclusions 33

76 3.3 Choice of nutrients and non-nutrient components of foods for nutrient-profiling..... 33

77 4 Conclusions..... 35

78 5 References..... 36

79 Appendices..... 48

80 Appendix A - Protocol for the provision of scientific advice on the development of harmonised

81 mandatory front-of-pack nutrition labelling and the setting of nutrient profiles for restricting

82 nutrition and health claims on foods (endorsed by the NDA Panel on 8 April 2021) 48

83 Appendix B – Survey in EU/EEA Member States on diet-related chronic diseases considered in

84 national Food Based Dietary Guidelines (FBDGs)..... 50

85 Glossary and/or abbreviations and/or acronyms..... 54

86

87

DRAFT

88 **1 Introduction**

89 There is evidence from human studies about the relationship between the intake of certain nutrients
90 and non-nutrient components of food and the development of obesity and other diet-related chronic
91 diseases that are of importance for public health in Europe. Cardiovascular diseases (CVD), diabetes
92 mellitus, obesity, osteoporosis, dental caries and cancer, but also iodine and iron deficiency, among
93 others, have been considered by several European countries as public health priorities when setting
94 food-based dietary guidelines (FBDGs) (see Appendix B, results of a questionnaire sent by EFSA to
95 EU/EAA countries).

96 According to the Global Burden of Disease (GBD) database¹, in 2019, around 12% of the EU population
97 (approx. 60 million people) were affected by CVD, with around 6 million new cases diagnosed per year.
98 Around 10% (approx. 49 million people) suffered from type 2 diabetes mellitus (T2DM) (2 million new
99 cases per year). Around 15% of adults were considered obese (BMI>30 kg/m², data from 2017)² and
100 more than 23 million individuals in the EU (i.e. approx. 5% of the population) are at high risk of
101 osteoporotic fractures (Kanis et al., 2021). Dental caries affects 20-90% of 6-year olds and almost
102 100% of adults.³ Also, some types of cancers are related to diet, in particular, cancers of the
103 gastrointestinal tract (WCRF/AICR, 2018).

104 A diet in line with science-based recommendations for food and nutrient intake is an important
105 determinant of health. Because diets are composed of multiple foods, overall dietary balance may be
106 achieved through complementation of foods with different nutrient profiles so that it is not necessary
107 for individual foods to match the nutrient profile of a nutritionally adequate diet. Nevertheless, individual
108 foods might influence the nutrient profile of the overall diet, depending on the nutrient profile of the
109 particular food and its intake, in terms of frequency and amount (EFSA, 2008).

110 The term 'nutrient profile' refers to the nutritional composition of a food or diet, whereas 'nutrient
111 profiling' refers to the classification of foods based on their nutritional composition for specific purposes
112 (e.g. nutrition education, product reformulation, product labelling to help consumers make informed
113 dietary choices, regulation of health claims, restriction of advertisement to children) (EFSA, 2008). The
114 World Health Organization (WHO) defines nutrient profiling as 'the science of classifying or ranking
115 foods according to their nutritional composition for reasons related to preventing disease and promoting
116 health' (WHO, 2015b; Storcksdieck genannt Bonsmann et al., 2020).

117 Several nutrient profiling models have been developed worldwide. A systematic review that took into
118 account publications up to 2016 identified 78 published nutrient profiling models (Labonté et al., 2018),
119 of which 56% were newly developed models and 44% were a modification of an existing model. The
120 models have been mainly drawn up for the purpose of establishing food standards for schools (n=27),
121 front-of-pack labelling (n=12), restricting marketing of foods to children (n=10) and regulating health
122 claims made on foods (n=7).

123 Nutrient profiling models may be established across the board, using the same criteria for all foods/food
124 categories, or may be specific to certain food categories. The models may be based either on thresholds
125 for individual nutrients or on an overall composite score that is the sum of scores attributed to foods
126 according to specific criteria (EFSA, 2008; Santos et al., 2021). The majority of the nutrient profiling
127 models identified by Labonté et al. (2018) were scoring systems, whereas three were based on
128 thresholds of nutrients and four were hybrid systems. The majority had more than one food category
129 to which different nutritional criteria were applied (ranging up to 99 categories). Only three models
130 applied the same criteria across the board and 12 consisted of two categories. All models included
131 nutrients and non-nutrient components of food that should be limited in the diet. These were mainly
132 sodium, saturated fatty acids (SFAs) and sugars. Eighty-six percent of the models also included food
133 groups (e.g. fruits, vegetables, nuts, legumes), nutrients (e.g. protein) and non-nutrient food

¹ <http://ghdx.healthdata.org/>

² https://ec.europa.eu/eurostat/databrowser/view/sdg_02_10/default/table?lang=en

³ <https://www.euro.who.int/en/health-topics/disease-prevention/oral-health/data-and-statistics#:~:text=In%20Europe%2C%2020%20%E2%80%9390%25,have%20experience%20of%20the%20disease>

134 components (e.g. dietary fibre) whose consumption should be increased. A recent systematic review of
135 existing nutrient profiling models, including, however, fewer models, shows similar results (Santos et
136 al., 2021).

137 An important consideration when establishing nutrient profiling models is the reference quantity to
138 which the nutrient content of a food is related, i.e. per serving size/portion, per weight/volume or per
139 energy content. The advantages and disadvantages of the different options have been reviewed
140 previously in detail by EFSA (2008). Finally, the validation of a nutrient profiling model is of importance
141 in order to ensure the correct classification of foods for the purpose for which the model has been
142 developed (Santos et al., 2021).

143 Front-of-pack (FOP) labelling is simplified nutrition information provided on the front of food packages
144 aiming at helping consumers with their food choices.⁴

145 According to WHO (WHO, 2019), FOP refers to '*nutrition labelling systems that:*

- 146 • *are presented on the front of food packages (in the principal field of vision) and can be applied*
147 *across the packaged retail food supply;*
- 148 • *comprise an underpinning nutrient profile model that considers the overall nutrition quality of*
149 *the product or the nutrients of concern for [non-communicable diseases] NCDs (or both); and*
- 150 • *present simple, often graphic information on the nutrient content or nutritional quality of*
151 *products, to complement the more detailed nutrient declarations usually provided on the back*
152 *of food packages.'*

153 FOP labelling may take different forms, as reviewed by the Joint Research Centre (JRC) of the European
154 Commission (Storcksdieck genannt Bonsmann et al., 2020).

155 Nutrient profiling models developed for the purpose of restricting nutrition and health claims have been
156 reviewed by EFSA (2008), Labonté et al. (2018) and Santos et al. (2021).

157 **1.1 Background as provided by the mandate requestor**

158 The Commission adopted on 20 May 2020 the Farm to Fork Strategy for a fair, healthy and
159 environmentally-friendly food system (COM(2020) 381 final), as part of the European Green Deal. The
160 strategy announces that to promote sustainable food consumption and facilitate the shift to healthy
161 and sustainable diets, the Commission will adopt measures to empower consumers to make informed,
162 healthy and sustainable food choices. In particular, the strategy announces that the Commission will
163 propose harmonised mandatory front-of-pack nutrition labelling. The strategy further announces that
164 to stimulate sustainable food processing and reformulation but also to facilitate the shift to healthier
165 diets, the Commission will set nutrient profiles to restrict the promotion (via nutrition and health claims)
166 of foods high in fat, sugars and salt.

167 The Farm to Fork Action Plan indicates that a proposal for harmonised mandatory front-of-pack nutrition
168 labelling and for the setting of nutrient profiles to restrict the promotion of foods high in salt, sugars
169 and/or fat will be submitted in Q4 2022.

170 On 20 May 2020, the Commission also published its Staff Working Document of the Evaluation of the
171 Nutrition and Health Claims Regulation (SWD(2020) 95 final)⁵, accompanying the Farm to Fork Strategy.
172 The evaluation assessed the impact of the nonsetting of nutrient profiles and whether nutrient profiles
173 are still fit for their purpose to ensure the objectives of the Claims Regulation. Overall, the evaluation
174 findings show that the specific objective pursued by the setting of nutrient profiles is still pertinent and
175 necessary to meet the objective of the Claims Regulation, which is a high level of consumer protection,
176 and that therefore, the setting of nutrient profiles needs to be further considered. Article 4 of Regulation

⁴ https://ec.europa.eu/food/safety/labelling-and-nutrition/food-information-consumers-legislation/nutrition-labelling_en

⁵ https://ec.europa.eu/food/sites/food/files/safety/docs/labelling_nutrition-claims_swd_2020-95_part-1.pdf

177 1924/2006 on Nutrition and Health Claims on Foods foresees that the European Commission shall
178 establish (by 19 January 2009) specific nutrient profiles that foods or certain groups of foods must
179 respect in order to bear nutrition and health claims. Following the Commission's request of 19 February
180 2007, EFSA adopted on 31 January 2008 the Scientific Opinion of the Panel on Dietetic Products,
181 Nutrition and Allergies on the setting of nutrient profiles for foods bearing nutrition and health claims.
182 Despite the initial progress, nutrient profiles have not yet been established at EU level given the high
183 controversy of the topic and strong opposition by some Member States in 2009, when the Commission
184 tried to establish them.

185 On 20 May 2020, the Commission also adopted its report on front-of-pack nutrition labelling⁶ (COM
186 (2020) 207 final), accompanying the Farm to Fork Strategy. The Report presents the main front-of-
187 pack nutrition labelling schemes currently implemented or being developed at EU level, as well as some
188 of the schemes implemented at international level. The report looks into consumer understanding and
189 impacts of the schemes, including on purchasing behaviour, food reformulation and the internal market.
190 It also addresses the positions of Member States and stakeholders and the question of possible EU
191 harmonisation. The report builds upon literature reviews and data gathered and analysed by the Joint
192 Research Centre⁷. The report concludes that front-of-pack schemes have the potential to help
193 consumers make health-conscious food choices and that evaluative schemes that use colour coding,
194 with or without a graded indicator, appear most promising for improving the healthfulness of
195 consumers' shopping baskets.

196 Nutrient profiling has various applications, including for health and nutrition claims and for front-of-
197 pack nutrition labelling schemes. There are three main approaches for applying nutrient (profiling)
198 criteria for front-of-pack labelling and the specific approach depends on the front-of-pack nutrition
199 labelling system used⁸.

200 The first typical approach to applying nutrient criteria is to enumerate the nutrient contribution that a
201 food makes to recommended nutrient intakes (e.g. Reference Intakes); information on individual
202 nutrients is kept separate. This approach is used in non-interpretive nutrient-specific front-of-pack
203 schemes⁹.

204 The second typical approach to applying nutrient profiling criteria¹⁰ is to set threshold amounts (i.e.
205 cut-off points) for individual nutrients, which divide nutrient contributions into categories that are either
206 graded (e.g. high, medium and low in the case of the traffic lights label) or binary (e.g. meet the
207 standard and do not meet the standard in the case of endorsement logos). Information on individual
208 nutrients is kept separate. For endorsement logos, products only display the logo when all relevant cut-
209 off points for individual nutrients are met¹¹.

210 The third typical approach is to apply algorithms to derive a consolidated score representing products'
211 overall nutritional profile. Information on individual nutrients is combined. The approach is used for
212 summary graded indicator schemes.

213 The second and third approaches differ from the first by interpreting the level of nutrient contribution
214 that a food makes to dietary recommendations, going beyond the provision of numeric information.

215 Applying nutrient profiling approaches for the purpose of front-of-pack nutrition labelling and for the
216 purpose of restricting nutrition and health claims on foods is an exercise that should take into account

⁶ https://ec.europa.eu/food/sites/food/files/safety/docs/labelling-nutrition_fop-report-2020-207_en.pdf

⁷ <https://ec.europa.eu/jrc/en/publication/eur-scientific-and-technical-research-reports/front-pack-nutrition-labelling-schemes-comprehensive-review>

⁸ WHO guiding principles and framework manual for front-of-pack labelling for promoting healthy diet (2019)

⁹ While such nutrient-specific schemes do provide some assessment of the contribution that a serving of food makes to nutrient intakes, such systems do not provide an evaluative judgement about how numerical values should be interpreted and, consequently, are referred to as a non-interpretive (WHO Health Evidence Network Synthesis Report 61)

¹⁰ For the second and third approach, the terminology 'nutrient profiling' criteria is used; nutrient profiling is the science of classifying or ranking foods according to their nutritional composition for reasons related to preventing disease and promoting health (<https://www.who.int/nutrition/topics/profiling/en/>)

¹¹ Endorsement logos are therefore also considered as 'summary labels'.

217 dietary recommendations, public health considerations, generally acceptable scientific evidence on the
218 relationship between diet, nutrition and health as well as other considerations of an
219 industrial/commercial, cultural and dietary/culinary nature. Applying nutrient profiling approaches for
220 front-of-pack labelling and for restricting claims should also stimulate product reformulation and should
221 take into account the variability of dietary habits and traditions.

222 1.2 Terms of Reference as provided by the mandate requestor

223 In accordance with Article 29(1)(a) of Regulation (EC) No 178/2002, the European Commission requests
224 the European Food Safety Authority to provide scientific advice for the development of harmonised
225 mandatory front-of-pack nutrition labelling and the setting of nutrient profiles for restricting nutrition
226 and health claims on foods. In particular, the Authority is requested to provide scientific advice on the
227 following:

- 228 • **Nutrients** of public health importance for European populations, **including non-nutrient**
- 229 **components** of food (e.g. energy, dietary fibre)
- 230 • **Food groups** which have important roles in diets of European populations and subgroups thereof
- 231 • **Choice of nutrients and other non-nutrient components of food for nutrient profiling**

232 *In providing scientific advice, the Authority is requested to consider the following:*

233 **Nutrients of public health importance for European populations, including non-nutrient**

234 **components of food (e.g. energy, dietary fibre)**

235 The consideration regarding nutrients as well as non-nutrient food components should be based on
236 evidence of a dietary imbalance in European populations that might influence the development of
237 overweight and obesity or diet-related diseases such as cardiovascular disease, or other disorders; they
238 can include nutrients and non-nutrient food components that might be consumed to excess, as well as
239 those for which intakes might be inadequate.

240 **Food groups which have important roles in diets of European populations and subgroups**

241 **thereof**

242 Consideration should be given to the food groups/food categories which have important roles in diets
243 of European populations and subgroups

- 244 • due to the quantities of energy, certain macro- and micronutrients, other substances of
245 physiological importance as well as for other non-nutrient food components contained in the food
246 group/food category,
- 247 • due to the role and importance of the food group/food category in the diet for the population in
248 general or, as appropriate, of certain risk groups including children,
- 249 • due to the overall nutritional composition of the food group/food category,
- 250 • due to the presence or absence of nutritional elements that have been scientifically recognised as
251 having an effect on health and
- 252 • due to effects on health of consuming the food group/food category.

253 **Choice of nutrients and other non-nutrient components of food for nutrient profiling**

254 The nutritional criteria and food components for nutrient profiling should aim to inform choice and
255 enable interpretation of food products against risks for diet-related noncommunicable diseases (NCDs)
256 and for promoting healthy diets.

257 The choice of nutrients of public health importance (e.g. sodium), including non-nutrient components
258 of food (e.g. energy, other substances of physiological importance such as fibre) should be based on
259 scientific evidence that underpins - directly or indirectly - the association of food components/food
260 groups/food categories and related public health outcomes.

261 1.3 Context of the assessment

262 Upon a request from the European Commission, in 2008, the NDA Panel provided advice on nutrient
263 profiling with the sole purpose of regulating nutrition and health claims made on foods (EFSA, 2008).
264 The purpose was to avoid that nutrition or health claims could mislead consumers as to the overall
265 nutritional composition of a food when trying to make 'healthy' choices in the context of a nutritionally
266 adequate diet. Nutrient profiling models aimed at restricting nutrition and health claims on foods were
267 not meant to communicate nutrition information to the consumer. When classifying foods as eligible to
268 bear claims, the potential of the food to adversely affect the overall dietary balance was the main
269 scientific consideration.

270 In the present mandate, the Commission requests EFSA to provide scientific advice for the development
271 of harmonised mandatory front-of-pack nutrition labelling and the setting of nutrient profiles for
272 restricting nutrition and health claims on foods. This means that the scientific advice provided by the
273 NDA Panel in 2008 should be extended for the purpose of helping consumers make 'healthy' choices
274 through FOP labelling, and thus the main scientific consideration should also include the potential of
275 foods to beneficially affect the overall dietary balance.

276 In the general principles for setting nutrient profiling models for the regulation of nutrition and health
277 claims made on foods (EFSA, 2008) and for setting FBDGs¹² at national level (EFSA NDA Panel, 2010d),
278 the NDA Panel noted that:

- 279
- 280 a) The nutrient profile of the overall (habitual) diet is an important determinant of health and the
281 nutrient profile of a nutritionally adequate diet is defined by science-based recommendations
282 for intakes of energy and nutrients (i.e. Dietary Reference Values (DRVs)).
283
 - 284 b) Because diets are composed of multiple foods, overall dietary balance may be achieved through
285 complementation of foods with different nutrient profiles, so that it is not necessary for
286 individual foods to match the nutrient profile of a nutritionally adequate diet. Nevertheless,
287 individual foods might influence the nutrient profile of the overall diet, depending on the
288 nutrient profile of the particular food and its intake, in terms of amount and frequency.
289
 - 290 c) For some foods, there is evidence of health benefits that cannot be attributed to their specific
291 content of nutrients (e.g. fruits and vegetables). The level of consumption of foods with
292 established relationships to health that are not nutrient specific should be considered when
293 establishing FBDGs for individual countries.
294
 - 295 d) For a number of nutrients and food groups, a dietary imbalance can increase the risk of obesity
296 and diet-related diseases (e.g. CVD, some cancers, T2DM, osteoporosis and dental disease)
297 that are of importance for public health in the EU. These include nutrients and foods that might
298 be consumed to excess, as well as those for which intakes might be inadequate.
299
 - 300 e) Nutrient profiling models should take into account the dietary role and importance of food
301 groups and their contribution of nutrients to the overall diet of the population (or specific
302 population groups), in order to ensure that some food items in food groups with an important
303 dietary role might be eligible to bear claims.
304
 - 305 f) The choice of nutrients to be included in nutrient profiling models should be driven by their
306 public health importance for EU populations.

307 The Panel notes that these scientific considerations could underpin the setting of nutrient profiling
308 models both for restricting claims on foods and for helping consumers to make 'healthy' food choices.

¹² FBDG constitute science-based policy recommendations in the form of guidelines for healthy eating

309

310 1.4 Interpretation of the Terms of Reference

311 The Panel understands that the scientific advice requested relates to the identification of:

- 312 a) **Nutrients and foods, including non-nutrient components of food** (e.g. energy,
313 dietary fibre), that are of importance for public health in European populations. These
314 include nutrients and foods that might be consumed in excess, as well as those for which
315 intakes might be inadequate, in the context of current dietary recommendations on healthy
316 diets either by European countries or independent scientific bodies.
- 317 b) **Food groups** with important dietary roles in European populations and subgroups thereof
318 owing to their nutrient composition and their (habitual) intake, as recognised by Member
319 States in FBDGs. FBDGs also make distinctions between different foods within these food
320 groups based on their potential to influence, beneficially or adversely, the overall dietary
321 balance for certain nutrients. The dietary roles of these food groups might differ across
322 Member States owing to the variability of dietary habits and traditions.
- 323 c) **Criteria that could guide the choice** of nutrients, including non-nutrient components
324 of food, **for the nutrient profiling of foods**, with the scope of developing harmonised
325 mandatory FOP nutrition labelling and the setting of nutrient profiles for restricting nutrition
326 and health claims on foods.

327 The Panel also understands that this mandate is not a request to develop a nutrient profiling model or
328 to provide advice on current profiling models already in use for different purposes.

329 The Panel further understands that the mandate is restricted to providing advice on the relationships
330 between nutrients, non-nutrient components, foods and food groups and diet-related chronic diseases
331 and does not cover any considerations related to the sustainability of the food chain. The Panel
332 acknowledges that, in addition to scientific considerations, other issues may be taken into account by
333 the European Commission in establishing nutrient profiling models for the above-mentioned purposes,
334 e.g. feasibility and product innovation.

335 2 Data and Methodologies

336 2.1 Data

337 The data used in the present opinion are review publications, in particular systematic reviews and meta-
338 analyses of human intervention and observational studies on nutritionally adequate diets, data from
339 the Global Burden of Disease framework, clinical practice guidelines, previous EFSA opinions, and the
340 priorities set by EU Member States in the context of their FBDGs and associated nutrient/food intake
341 recommendations. Relevant publications have been retrieved through comprehensive searches in
342 PubMed. Priority was given to previous assessments of EFSA, followed by systematic reviews and
343 associated meta-analyses. In few cases, results of individual human studies have been considered,
344 when this was relevant.

345 2.2 Methodologies

346 For this scientific assessment, a protocol (Appendix A) has been developed in line with existing
347 methodology (EFSA, 2020).

348 The nutrients and non-nutrient components of food of public health importance for European
349 populations that are consumed in excess or in inadequate¹³ amounts have been identified based on
350 expert knowledge and from a questionnaire sent by EFSA to EU/EAA countries through EFSA focal
351 points (see Appendix B).

¹³ In the context of this Opinion inadequate is to be interpreted as insufficient

352 2.3 Definitions

353 In the context of this Opinion, the following definitions apply:

- 354 ▪ Nutrient profile: Nutritional composition of a food or diet.
- 355 ▪ Nutrient profiling: Classification of foods based on their nutritional composition for specific
356 purposes.
- 357 ▪ Population Reference Intake (PRI): The level of (nutrient) intake that is adequate for almost all
358 (97.5%) in a population group.
- 359 ▪ Average Requirement (AR): The level of (nutrient) intake that is adequate for half of the people
360 in a population group, given a normal distribution of requirements.
- 361 ▪ Adequate Intake (AI): This value is estimated when a PRI cannot be established because an
362 AR cannot be determined. It can, for example, be based on the average observed daily level
363 of intake by a population group (or groups) of apparently healthy people that is assumed to be
364 adequate.
- 365 ▪ Reference Intake Range for macronutrients (RI): The intake range for macronutrients,
366 expressed as % of the energy intake (E%). These apply to ranges of intakes that are adequate
367 for maintaining health and are associated with a low risk of selected chronic diseases.
- 368 ▪ Tolerable Upper Intake Level (UL): The maximum level of total chronic daily intake of a nutrient
369 (from all sources) judged to be unlikely to pose a risk of adverse health effects to humans.
- 370 ▪ Dietary Reference Values (DRVs): A set of nutrient reference values that include AR, PRI, AI,
371 RI and UL. These values guide professionals on the amount of a nutrient needed to maintain
372 health in an otherwise healthy individual or group of people.
- 373 ▪ Cardiovascular disease (CVD): A general term referring to conditions affecting the heart and
374 blood vessels. The most common is coronary heart disease. Stroke, transient ischemic attack,
375 arrhythmia, peripheral vascular disease and aortic disease are other examples of CVD.¹⁴
- 376 ▪ Coronary heart disease (CHD): The most common form of CVD. A pathological process
377 characterised by atherosclerotic plaque accumulation in the coronary arteries, whether
378 obstructive or non-obstructive (Knuuti et al., 2019).
- 379 ▪ Cardiovascular event: Used to denote the composite of a variety of adverse events related to
380 the cardiovascular system.
- 381 ▪ Type 2 diabetes mellitus (T2DM): Diabetes is a group of metabolic diseases characterized by
382 hyperglycaemia resulting from defects in insulin secretion, insulin action, or both. T2DM
383 encompasses individuals who have insulin resistance and usually have relative insulin deficiency
384 (American Diabetes Association, 2014).
- 385 ▪ Dietary fibre: In EFSA's scientific opinion on DRVs for carbohydrates and dietary fibre (EFSA
386 NDA Panel, 2010b), dietary fibre denotes all non-digestible carbohydrates. The definition of
387 dietary fibre for regulatory purposes in the EU is laid down in Regulation (EU) No 1169/2011.¹⁵
- 388 ▪ Saturated fatty acids (SFAs): SFAs are characterised by carbon chains that contain no double
389 bonds, i.e. only single bonds.

¹⁴ <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cardiovascular-disease>

¹⁵ Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC and Commission Regulation (EC) No 608/2004. OJ L 304, 22.11.2011, p. 18–63.

- 390 ▪ *trans*-Fatty acids (TFAs): Unsaturated fatty acids (fatty acids with ≥ 1 double bond) that contain
391 at least one double bond in the *trans* configuration (i.e. hydrogen atoms are positioned on the
392 opposite side of the carbon chain at a double bond).
- 393 ▪ *cis*-Fatty acids: Unsaturated fatty acids (fatty acids with ≥ 1 double bond) in which all double
394 bonds are in the *cis* configuration (i.e. the hydrogen atoms are positioned at the same side of
395 the carbon chain at a double bond).
- 396 ▪ Monounsaturated fatty acids (MUFAs): Fatty acids characterised by one double bond in the
397 carbon chain.
- 398 ▪ Polyunsaturated fatty acids (PUFAs): Fatty acids characterised by more than one double bond
399 in the carbon chain.
- 400 ▪ Long-chain (LC)-PUFAs: PUFAs with a chain length of ≥ 20 carbon atoms and ≥ 3 double bonds.
- 401 ▪ Omega 3 (n-3) fatty acids: PUFAs characterised by the presence of a double bond, three carbon
402 atoms away from the terminal methyl group in their chemical structure.
- 403 ▪ Omega 6 (n-6) fatty acids: PUFAs characterised by the presence of a double bond, six carbon
404 atoms away from the terminal methyl group in their chemical structure.
- 405 ▪ Linoleic acid (LA): Essential PUFA, precursor of the n-6 family, with 18 carbon atoms and two
406 *cis* double bonds (C18:2, n-6).
- 407 ▪ alpha-Linolenic acid (ALA): Essential PUFA, precursor of the n-3 family, with 18 carbon atoms
408 and two *cis* double bonds (C18:3, n-3).
- 409 ▪ Arachidonic acid (ARA): PUFA of the n-6 group with 20 carbon atoms and four *cis* double bonds
410 (C20:4, n-6).
- 411 ▪ Eicosapentaenoic acid (EPA): LC-PUFA of the n-3 group with 20 carbon atoms and five *cis*
412 double bonds (C20:5, n-3).
- 413 ▪ Docosahexaenoic acid (DHA): LC-PUFA of the n-3 group with 22 carbon atoms and six *cis*
414 double bonds (C22:6, n-3).
- 415 ▪ Total sugars: Main types of mono- and disaccharides found in mixed diets (i.e. glucose,
416 fructose, galactose, sucrose, lactose, maltose and trehalose) (EFSA NDA Panel, 2021).¹⁶
- 417 ▪ Added sugars: Mono- and disaccharides added to foods as ingredients during processing or
418 preparation at home, and sugars eaten separately or added to foods at the table.
- 419 ▪ Free sugars: Added sugars plus sugars naturally present in honey, syrups, fruit juices and fruit
420 juice concentrates.
- 421 ▪ Core food groups: Food groups supplying most macro- and micronutrients in the diet as
422 recommended in FBDGs.
- 423 ▪ Non-core food groups: Food groups for which FBDGs generally advise to limit consumption.

¹⁶ According to European legislation (Regulation (EU) No 1169/2011), sugar alcohols (polyols) such as sorbitol, xylitol, mannitol and lactitol, which are low-calorie sugar replacers that can be used in foods also for purposes other than sweetening, are 'carbohydrates' not included under the term 'sugars' and will not be considered in this opinion. Alongside polyols, other substances used as sugar replacers and other mono- or disaccharides present in the diet in marginal amounts are not included in the term 'sugars' for the purpose of this assessment (e.g. isomaltulose, D-tagatose)

424 **3 Assessment**

425 **3.1 Nutrients and non-nutrient components of foods of public health** 426 **importance for European populations**

427 Harmonised data on food intakes of infants, children, adults, older people, pregnant and lactating
428 women in 21 European Member States plus the UK are available in the EFSA Comprehensive Food
429 Consumption Database.¹⁷ The methods used for estimating dietary intakes varied among countries and
430 even within countries. Nutrient intakes for these population groups have been calculated using the
431 EFSA Nutrient Composition Database¹⁸ (Roe et al., 2013). The database covers approximately 1,750
432 food entries and additional facet descriptors included in the EFSA food classification system (FoodEx2),
433 and contains data for energy, macro- and micronutrients from national food composition databases up
434 to 2012, provided by 14 national food database compiler organisations. These data have been used by
435 EFSA to provide intake estimates, mostly for micronutrients, in scientific opinions on DRVs for nutrients
436 since 2014. The nutrients for which such intake estimates from the EFSA Comprehensive Food
437 Consumption Database are available are sugars, choline, niacin, riboflavin, thiamine, vitamin A, vitamin
438 B₆, vitamin B₁₂, vitamin E, vitamin K, vitamin D (infants only), calcium, copper, iron, magnesium,
439 phosphorus, potassium, selenium and zinc and these have been used in the present Opinion. For
440 nutrients for which such harmonised intake estimates are not available, the Opinion is mostly based on
441 nutrient intakes derived from national dietary surveys cited in the respective EFSA Opinions on DRVs.

442 **3.1.1 Nutrients and non-nutrient components of food for which intakes might** 443 **exceed recommended levels in most population groups and countries in** 444 **Europe**

445 **3.1.1.1 Energy**

446 It is well-established that a sustained positive energy balance, i.e. when energy intake exceeds
447 requirements, leads to an accumulation of body fat (Hall et al., 2011). This may ultimately result in the
448 development of overweight or obesity. Overweight and obesity increase the risk of developing diet-
449 related chronic diseases, such as T2DM or CVD, and some cancers (World Cancer Research Fund and
450 American Institute for Cancer Research, 2018). Overweight and obesity have also been associated with
451 a higher all-cause mortality (Mongraw-Chaffin et al., 2015; Aune et al., 2016b; Global BMI Mortality
452 Collaboration et al., 2016). Evidence from randomised controlled trials (RCTs) shows that weight loss
453 in obese adults improves cardiometabolic risk factors in a dose-response manner, namely blood
454 pressure, blood lipid profile and blood glucose control. It has also been shown in RCTs that weight loss,
455 and its maintenance over time, significantly decreases the risk of developing T2DM in obese individuals
456 (Jensen et al., 2014) and reduces the risk of all-cause mortality (Ma et al., 2017).

457 Data on the prevalence of overweight (i.e. body mass index (BMI) ≥ 25 kg/m²) or obesity (i.e. BMI ≥ 30
458 kg/m²) in adults in Europe are available from Eurostat¹⁹, the Global Obesity Observatory²⁰ and WHO.²¹
459 Estimates from the different data providers differ to a certain extent, possibly owing to the different
460 assessment techniques (self-reports vs. measured weights and heights) and populations studied.
461 However, they indicate that the prevalence of overweight or obesity in EU Member States ranges
462 between around 50 to 75% in males and between around 35 to 65% in females. The prevalence of
463 obesity ranges between around 10 to 30% in males and 10 to 35% in females, depending on the
464 country.

465 Combining data of different age groups from 2007 to 2019 and using different cut-offs for defining
466 overweight and obesity (i.e. WHO, International Obesity Task Force (IOTF), Centers for Disease Control

¹⁷ <https://www.efsa.europa.eu/en/food-consumption/comprehensive-database>

¹⁸ <https://www.efsa.europa.eu/en/microstrategy/food-composition-data>

¹⁹ https://ec.europa.eu/eurostat/databrowser/view/HLTH_EHIS_BM1E__custom_970518/default/table?lang=en

²⁰ <https://data.worldobesity.org/>

²¹ <https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/ncd-risk-factors>

467 (CDC) or other), the Global Observatory for Obesity reports a prevalence of overweight or obesity in
 468 children in EU Member States of around 10 to 45%.²² WHO data in 5 to 19-year-old children indicate a
 469 prevalence of overweight or obesity (BMI > +1 SD above the median) between 25 and 40% in boys and
 470 between 20 and 35% in girls. The prevalence of obesity (BMI > +2 SD above the median) is between 8
 471 and 17% in boys and between 5 and 11% in girls.

472 ARs for energy were set by EFSA in 2013 (EFSA NDA Panel, 2013) for children and adults, by sex,
 473 assuming a normal body weight, based on the calculated resting energy expenditure and considering
 474 different physical activity levels. For infants, the AR was based on measurements of total energy
 475 expenditure in healthy, full-term and initially breast-fed infants, plus the energy requirement for growth.
 476 A PRI was not derived, as this implies an energy intake that is above the requirement for almost all
 477 individuals in a group. As the AR still exceeds the energy needs of half of the individuals in the group,
 478 it can be used to assess energy intakes in groups of healthy people but is of limited value for individuals
 479 (EFSA NDA Panel, 2013).

480 Lacking information on the physical activity level of the individuals included in dietary surveys in
 481 summary publications, and owing to the complex mechanisms regulating energy balance, it is difficult
 482 to establish whether energy intakes in a population exceed energy requirements solely based on intake
 483 data. However, considering the high prevalence of overweight and obesity in Europe, it can be inferred
 484 that energy intakes are higher than required to maintain a normal body weight (BMI of 18.5 to 24.9
 485 kg/m²) in a large proportion of the European population.

486 While DRVs for protein are set based on physiological requirements (see Section 3.1.2.1), those for fat
 487 and digestible carbohydrates are not, but need to reflect the difference between total energy
 488 requirement and energy provided by protein. Digestible carbohydrates are not essential and
 489 physiological requirements for essential fatty acids cover only part of the energy needs. Therefore, the
 490 RIs for digestible carbohydrates (45 to 65 E%) and total fat (20 to 35 E%) have been derived by EFSA
 491 (EFSA NDA Panel, 2010c, b) based on their effects on the blood lipid profile (i.e. the upper bound for
 492 carbohydrates and the lower bound for fat) and the observation that high fat diets may promote energy
 493 intake and weight gain (i.e. the upper bound for fat and the lower bound for carbohydrates). Also,
 494 practical considerations (e.g. observed levels of intake, achievable dietary patterns) have been taken
 495 into account. Owing to the positive impact of energy restriction and weight loss on cardiometabolic risk
 496 factors and chronic disease risk, the specific effect of individual macronutrients on these endpoints is
 497 generally assessed in isocaloric exchange with each other (Willett et al., 1997).

498 Energy-containing food constituents (macronutrients, dietary fibre, alcohol, polyols) have been
 499 assigned energy conversion factors for labelling purposes²³, as shown in Table 1. In some cases (e.g.
 500 glycaemic carbohydrates, dietary fibre, polyols), such energy-conversion factors are average values
 501 that reflect the energy provided by the food constituent as found in mixed diets or are average values
 502 set based on practical considerations. They do not necessarily reflect the energy provided by specific
 503 components in the group (Elia and Cummings, 2007).

504 **Table 1** Energy conversion factors for energy-containing food constituents for labelling purposes

Food constituent	Energy conversion factor
Fat	9 kcal/g (37 kJ/g)
Alcohol	7 kcal/g (29 kJ/g)
Protein	4 kcal/g (17 kJ/g)
Glycaemic carbohydrates	4 kcal/g (17 kJ/g)
Polyols	2.4 kcal/g (10 kJ/g)
Dietary fibre	2 kcal/g (8 kJ/g)

²² Data on the prevalence of obesity alone in children are not available from this data source

²³ Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC and Commission Regulation (EC) No 608/2004. OJ L 304, 22.11.2011, p. 18–63

505

506 Although energy intake appears more important than the macronutrient composition of diets for weight
507 loss and the prevention of weight gain, there is some evidence that diets with a moderate fat content
508 (<30-35 E%) favour lower energy intake, weight loss and prevent weight gain as compared to energy
509 dense diets containing >35 E% as fat (EFSA NDA Panel, 2010c). Guidelines for the prevention and
510 management of uncomplicated obesity²⁴ (NICE, 2015; Yumuk et al., 2015) recommend limiting energy
511 intake and decreasing the consumption of energy-dense foods, among other interventions, both to
512 prevent excessive weight gain and manage overweight and obesity.

513 Taking into account the high prevalence of overweight and obesity in Europe, the Panel considers that
514 a reduction in energy intake is of public health importance for European populations.

515 **3.1.1.2 Fat**

516 Fat is an important source of energy and facilitates the absorption of fat-soluble dietary components
517 such as fat-soluble vitamins. Fats and oils are also important sources of essential fatty acids (i.e. LA
518 and ALA).

519 An RI has been established for total fat between 20 E% and 35 E% for adults, suggesting that wide
520 ranges of total fat intake are compatible with nutritionally adequate diets. The lower bound corresponds
521 to the lowest observed intakes in European countries with no overt signs of deficiencies and no adverse
522 effects on blood lipids. The upper bound is based on evidence that moderate fat intakes may favour
523 lower energy intake, weight loss and prevent weight gain, although it is acknowledged that total fat
524 intakes > 35 E% may be compatible with both good health and normal body weight, depending on
525 dietary patterns and the level of physical activity (EFSA NDA Panel, 2010c).

526 While the RI for total fat is partly based on practical considerations (e.g. current levels of intake,
527 achievable dietary patterns), the fatty acid composition of the diet is an important determinant that
528 influences blood lipid concentrations and CVD risk. Under isocaloric conditions, the most favourable
529 blood lipoprotein profile for atherosclerosis risk prevention is achieved by replacing mixtures of SFAs
530 and TFAs with *cis*-MUFAs (mostly oleic acid) and/or mixtures of *cis*-PUFAs (mostly the n-6 *cis*-PUFA LA,
531 the n-3 *cis*-PUFA ALA and the n-3 LC-PUFAs EPA and DHA). These effects are dose-dependent (EFSA
532 NDA Panel, 2010c, 2011d, b).

533 The main dietary determinant of blood low-density lipoprotein (LDL)-cholesterol concentrations is
534 saturated fat. Dietary cholesterol has a similar dose-response effect on blood LDL-cholesterol, but it is
535 consumed in considerably lower daily amounts (in the milligram range). Similarly, the impact of ARA (a
536 n-6 *cis*-PUFA) and of EPA and DHA on the blood lipid profile is expected to be low considering the low
537 daily consumption (in the milligram range) in European diets as compared to SFAs.

538 Although the replacement of mixtures of SFAs and TFAs by mixtures of *cis*-MUFAs and/or mixtures of
539 *cis*-PUFAs results in a more favourable blood lipid profile for ischemic CVD prevention, DRVs for SFAs,
540 TFAs, *cis*-MUFA or *cis*-PUFA could not be set by EFSA based on this endpoint for different reasons that
541 are explained in the following.

542 Mixtures of SFAs and TFAs were shown to increase LDL-cholesterol concentrations in a dose-response
543 manner as compared to carbohydrates, mixtures of *cis*-MUFAs and mixtures of *cis*-PUFAs, and to
544 increase CVD risk compared to *cis*-PUFAs (mainly LA). Owing to the linearity of the dose-response, a
545 UL could not be established. The Panel considered that the intake of SFAs and TFAs should be as low
546 as possible in the context of a nutritionally adequate diet.

547 *cis*-MUFAs have no known specific role in preventing or promoting diet-related diseases (EFSA NDA
548 Panel, 2010c; Schwingshackl et al., 2021) and hence no DRV has been set.

²⁴ Obesity without other morbidities

549 In view of the different metabolic effects of the various dietary *cis*-PUFAs, no DRVs were established
550 by EFSA for either total *cis*-PUFAs or the n-3/n-6 ratio.

551 There is an inverse (i.e. beneficial) relationship between the intake of LA and blood LDL-cholesterol
552 concentrations, while this relationship is positive (also beneficial) for HDL-cholesterol concentrations.
553 In addition, LA lowers fasting blood triglyceride concentrations when compared to carbohydrates, and
554 LA, when replacing mixtures of SFAs, decreases cardiovascular events in the population (EFSA NDA
555 Panel, 2010c). All these relationships are linear and dose-dependent, with no threshold value. While
556 ALA has similar effects on blood lipids than LA, its relationship with CVD risk when replacing SFAs is
557 less established. In both cases, data on blood lipids and chronic disease risk reduction could not be
558 used to establish a DRV. AIs for these essential fatty acids were derived from the lowest estimated
559 mean intakes of various population groups from a number of European countries where overt deficiency
560 symptoms are not present. For adults, the AI for LA is 4 E% and for ALA 0.5 E%. Their relative
561 contribution to the blood lipid profile and CVD risk when replacing SFAs and TFAs in the diet could in
562 part depend on the different amounts in which they are consumed.

563 Conversely, an AI of 250 mg/day for EPA and DHA combined was derived based on primary CVD risk
564 prevention. At these levels of EPA and DHA intake, other mechanisms than their effect on the blood
565 lipid profile (e.g. antiarrhythmic effects) may be more important, as explained in Section 3.1.2.2. on
566 EPA and DHA.

567 In the context described above, SFAs and TFAs will be considered as nutrients that may be consumed
568 in excess, whereas EPA and DHA will be considered as nutrients for which the intake may be inadequate,
569 in both cases in relation to CVD disease risk.

570 3.1.1.3 Saturated fatty acids

571 It is well established that the fatty acid composition of the diet is an important determinant of blood
572 lipid concentrations and CVD risk. Under isocaloric conditions, the most favourable lipoprotein profile
573 for atherosclerosis risk prevention is achieved by replacing SFAs and TFAs in mixed diets with *cis*-MUFAs
574 (mostly oleic acid) and/or mixtures of *cis*-PUFAs (mostly the n-6 LA, the n-3 ALA and the n-3 LC-PUFAs
575 EPA and DHA). These effects are dose dependent. (EFSA NDA Panel, 2010c, 2011d, b).

576 There is a differential effect of different SFAs on blood lipid concentrations. While lauric, myristic and
577 palmitic acids raise blood LDL-cholesterol when replacing carbohydrates, the effect of stearic acid is
578 more neutral (EFSA NDA Panel, 2010c, f). However, fatty acids occur as mixtures in foods and foods
579 rich in stearic acid often contain significant amounts of palmitic acid and other SFAs that increase blood
580 LDL-cholesterol concentrations (EFSA NDA Panel, 2010f). Therefore, the effect of mixtures of SFAs as
581 present in mixed diets is considered below.

582 It has been consistently demonstrated that there is a positive and causal relationship between blood
583 LDL-cholesterol concentrations and the risk of developing ischemic CVD, and that the reduction in
584 disease risk is proportional to the reduction of LDL-cholesterol concentrations (EFSA NDA Panel, 2018;
585 Mach et al., 2020). Since there was no evidence for a threshold below which mixtures of SFAs do not
586 raise LDL-cholesterol concentrations at the levels of intake observed in mixed diets, EFSA could not
587 establish a UL for SFAs, but considered that intakes should be as low as possible in the context of a
588 nutritionally adequate diet compatible with current dietary patterns and traditions in European
589 populations. Several Member States have recommended upper bounds of intake that are mostly in the
590 range of 8-10 E%.²⁵

591 Despite the well-established LDL-cholesterol-raising effects of SFAs, some meta-analyses of
592 observational studies failed to show a positive association between the intake of SFAs in mixed diets
593 and CVD risk in isocaloric exchange with other macronutrients (Siri-Tarino et al., 2010; de Souza et al.,
594 2015; Zhu et al., 2019; Kang et al., 2020). Several possible explanations have been advanced. On the
595 one hand, it has been proposed that the relationship may depend on the food matrices in which SFAs

²⁵ https://knowledge4policy.ec.europa.eu/health-promotion-knowledge-gateway/dietary-fats-table-4_en

596 are consumed, and that other nutrient and/or non-nutrient components of SFA-rich foods may modify
597 the risk of developing CVD (Mozaffarian et al., 2010; Mozaffarian, 2016; Astrup et al., 2020). On the
598 other hand, it is possible that, under isocaloric conditions, the health benefits of reducing SFAs in
599 relation to ischemic CVD risk prevention largely depend on the macronutrient by which they are replaced
600 in the diet. For example, while the CVD risk-lowering effect of *cis*-PUFAs (primarily LA and n-3 LC-PUFA)
601 are sizeable, no benefit is obtained from replacing SFAs with refined carbohydrates (e.g. sugars) (Briggs
602 et al., 2017; Visseren et al., 2021).

603 The SFA content of fats and oils is variable. The highest percentages of SFAs, expressed as % of total
604 fatty acids, are found in coconut oil (about 90%), palm kernel oil (about 85%), cocoa butter (about
605 60%), butter, palm oil, lamb fat (all about 50%), beef fat (about 45%) and pork fat (about 40%). The
606 relative proportion of individual SFAs in different food sources also differs. The major SFA in palm oil
607 and butter is palmitic acid, while coconut oil and palm kernel oil contain lauric acid as the predominant
608 fatty acid (EFSA NDA Panel, 2010c; Devi and Khatkar, 2018). The saturated fat component of beef,
609 lamb and pork is characterised by high amounts of palmitic and stearic acid (Wood et al., 2007).

610 In a review of sources and dietary intakes of fatty acids in Europe, Eilander et al. (2015) reported that
611 the main contributors to SFA intake were dairy (i.e. 17-41%), fats and oils (9-37%), meat and meat
612 products (15-30%), cake and pastry/desserts and sugar/preserve confectionary (reported without
613 percentage contribution to overall SFA intake). Only in Finland and the UK, were cereals and cereal
614 products also significant contributors to SFA intake (16-18%). The authors noted that data on the fatty
615 acid composition of some foods listed in national food composition databases are incomplete indicating
616 that the actual SFA, *cis*-MUFA and *cis*-PUFA intakes calculated based on these incomplete composition
617 data may have been underestimated.

618 In the food consumption surveys considered in the Scientific Opinion on DRVs for fats (EFSA NDA Panel,
619 2010c), mean intakes of SFAs in most EU Member States were above the recommended upper bounds
620 of intake of 8-10 E%. This is in agreement with more recent publications (Micha et al. (2014), Eilander
621 et al. (2015) and the European Commission²⁶). Intake data on individual SFAs could not be retrieved.

622 As SFAs increase LDL-cholesterol concentrations, an established risk factor for ischemic CVD, and the
623 majority of European populations exceed the upper bounds of intake recommended by some Member
624 States, the Panel considers that a reduction in intake of SFAs as present in mixed diets is of public
625 health importance for European populations.

626 **3.1.1.4 Trans fatty acids**

627 TFAs increase blood LDL-cholesterol concentrations in a linear dose-dependent manner to a similar
628 extent to SFAs. In addition, and different from SFAs, TFAs reduce blood high-density lipoprotein (HDL)-
629 cholesterol concentrations and increase the total cholesterol to HDL-cholesterol ratio (EFSA NDA Panel,
630 2010c; Mach et al., 2020). High intakes of TFAs have been associated with an increased risk of ischemic
631 CVD (Bendsen et al., 2011).

632 Owing to the positive (i.e. unfavourable) and linear dose-response relationship between the intake of
633 TFAs and adverse effects on the blood lipid profile, EFSA could not establish a UL for TFAs. However,
634 several European Member States have recommended upper bounds of intake for TFAs <1-2 E% by
635 considering what is practically achievable within the context of a nutritionally adequate diet based on
636 known patterns of intake of foods and nutrients in specific populations (EFSA NDA Panel, 2010c).

637 TFAs are naturally present in dairy products and meat from ruminants, usually at concentrations
638 between 2 and 9% of total fat (Mouratidou et al., 2014). They may also originate from deodorisation
639 of vegetable oils and from heating oils at temperatures >220°C, such as in deep frying (EFSA NDA
640 Panel, 2010c). A major source of TFAs in the diet are partially hydrogenated oils that are used in the

²⁶ https://knowledge4policy.ec.europa.eu/health-promotion-knowledge-gateway/dietary-fats-5b_en

641 manufacturing of margarines and spreads, fine bakery wares, and fillings of confectionary, among
642 others (Mach et al., 2020).

643 Intakes of TFAs have decreased considerably in Europe owing to reformulation of food products.
644 Already in 2004, mean intakes of TFAs were close to 1-2 E% in most European countries (EFSA NDA
645 Panel, 2010c). In a report of the JRC of the European Commission published in 2014 (Mouratidou et
646 al., 2014) that considered data from 13 studies published between 2006 and 2013, mean intakes of
647 TFAs were at 1 E% or below in all countries and population groups. TFAs intakes >1 E% were observed
648 in 25% of the surveyed individuals between the age of 20 and 30 years, the age group with the highest
649 intakes. However, even in this population group, maximum intakes were around 1.2 E%. In addition,
650 as of April 2021, food products that are sold within the European Union may not contain industrially
651 produced TFAs in amounts exceeding 2% of total fat.²⁷ This is expected to further reduce the
652 consumption of TFAs in the EU.

653 The Panel notes that the adverse health effects of diets high in TFAs are well documented. The Panel
654 also notes, however, that mean intakes of TFAs in most European countries and population groups are
655 at or below upper bounds of intakes recommended by some Member States within the context of
656 nutritionally adequate diets. The implementation of current European legislation limiting the use of
657 industrially produced TFAs is expected to further reduce intakes.

658 **3.1.1.5 Dietary sugars**

659 There is wide consensus that the intake of dietary sugars is causally related to the development of
660 dental caries at all ages (Jepsen et al., 2017). There is also evidence that high intakes of added and
661 free sugars increase the risk of developing chronic metabolic diseases including obesity, non-alcoholic
662 fatty liver disease, T2DM, dyslipidaemia and hypertension, possibly through an increase in energy intake
663 and body weight, among other mechanisms (WHO, 2015a; EFSA NDA Panel, 2021).

664 In its draft Scientific Opinion on the UL for dietary sugars (released for public consultation), the NDA
665 Panel concluded that the available scientific evidence did not allow to derive a UL or a safe level of
666 intake for dietary sugars because, whenever dose-response relationships between the intake of dietary
667 sugars and disease risk could be explored, these were positive and linear, and a level of sugar intake
668 at which the risk of disease is not increased could not be established (EFSA NDA Panel, 2021). The
669 Panel considered, however, that based on dental caries risk, the intake of total sugars should be as low
670 as possible within the context of a nutritionally adequate diet. The Panel also considered that, based
671 on the risk of developing chronic metabolic diseases and on dental caries risk, the intake of added and
672 free sugars should be as low as possible. The Panel noted that, at levels of added or free sugars intake
673 below 10 E%, the uncertainty is high regarding the shape and direction of the relationships between
674 the intake of added and free sugars and chronic metabolic disease risk.

675 Several authorities have set recommendations for added or free sugars below 10 E%, or below 5 E%,
676 based on various health endpoints, including chronic metabolic diseases and dental caries. Typically,
677 such recommendations also reflect a judgement of what level of sugar intake is practically achievable
678 within the context of a nutritionally adequate diet based on known patterns of intake of foods and
679 nutrients in specific populations.

680 The main dietary source of added sugars in Europe is sucrose added at the table and to processed
681 foods, while fructose-glucose syrups (isoglucose)²⁸ are increasingly used as a substitute for sucrose in
682 processed foods and beverages due to their higher sweetness, technological characteristics, and lower
683 price.

²⁷ Commission Regulation (EU) 2019/649 of 24 April 2019 amending Annex III to Regulation (EC) No 1925/2006 of the European Parliament and of the Council as regards trans fat, other than trans fat naturally occurring in fat of animal origin. OJ L 110, 25.4.2019, p. 17–20

²⁸ Council Directive 2001/111/EC of 20 December 2001 relating to certain sugars intended for human consumption. OJ L 10, 12.1.2002, p. 53–57

684 Food groups mostly contributing to the intake of added and free sugars in European countries are
685 'sugar and confectionery' (i.e. table sugar, honey, syrups, confectionery and water-based sweet
686 desserts), followed by beverages (sugar-sweetened soft and fruit drinks, fruit juices) and fine bakery
687 wares. The main difference between the intake of added and free sugars is accounted for by fruit juices.
688 In infants, children and adolescents, sweetened milk and dairy products are also major contributors to
689 mean intakes of added and free sugars. Different from total sugars, added and free sugars mainly
690 originate from non-core food groups, except for milk and dairy products in young consumers.

691 There is high variability in the intake of added and free sugars across population groups and countries
692 in Europe. In consumers of certain food groups, intakes of added and free sugars exceed the
693 recommended intakes in most European countries.

694 Taking into account the well-established positive relationships between a) the intake of dietary sugars
695 (total/added/free) and dental caries risk and b) the intake of added and free sugars and the risk of
696 developing chronic metabolic diseases, and that intakes of added and free sugars in consumers of
697 certain food groups exceed the recommended intakes in most European countries, the Panel considers
698 that a reduction in the intake of added and free sugars is of public health importance for European
699 populations. The Panel notes that decreasing the intake of added and free sugars would decrease the
700 intake of total sugars to a similar extent.

701 **3.1.1.6 Sodium**

702 The positive (i.e. unfavourable) and causal relationship between the intake of dietary sodium and blood
703 pressure is well established. High sodium intakes increase blood pressure and the risk of hypertension,
704 which is a risk factor for CVD and chronic kidney disease (Williams et al., 2018; Arnett et al., 2019;
705 EFSA NDA Panel, 2019b; Visseren et al., 2021).

706 In 2019, EFSA established a safe and adequate intake for sodium of 2.0 g/day for adults and children
707 from 11 years of age based on the relationship between sodium intake, blood pressure values, and risk
708 of CVDs (composite endpoint) including coronary heart disease and stroke in adults (EFSA NDA Panel,
709 2019b). The same year, the National Academy of Sciences in the US (NASEM, 2019) established a
710 Chronic Disease Risk Reduction Intake (CDRR) for sodium based on the beneficial effect of reducing
711 sodium intake on CVD risk, risk of hypertension, systolic blood pressure, and diastolic blood pressure.
712 For individuals 14 years of age and older, sodium intakes should be reduced if above 2.3 g/day. Neither
713 body could establish a UL for sodium.

714 Unprocessed foods and drinking water contain sodium, albeit in low amounts. The sodium content of
715 processed foods can vary substantially across countries, reflecting dietary habits and taste preferences.
716 It may also be influenced by technological considerations and by reformulation of processed foods in
717 response to public health policies. Also, large variations exist in the sodium content of foods belonging
718 to the same group. Sauces (particularly Asian ones), processed meat, cheese, savoury snacks and
719 canned fish are the food groups with the highest sodium content (Webster et al., 2010; Ni Mhurchu et
720 al., 2011; Capuano et al., 2013; Eyles et al., 2013; EFSA NDA Panel, 2019b), while the main contributors
721 to sodium intake in European populations are bread, processed meat and cheese (European
722 Commission, 2012; Kloss et al., 2015; EFSA NDA Panel, 2019b).

723 Sodium intakes have been estimated from urinary sodium excretion data collected in 18 European
724 countries (EFSA NDA Panel, 2019b). These data showed that mean sodium intakes in adults and
725 children exceeded the safe and adequate level of intake.

726 Taking into account the well-established relationships between sodium intake, blood pressure and CHD
727 risk, and that the majority of European populations exceed the safe and adequate level of intake, the
728 Panel considers that a reduction in the intake of dietary sodium is of public health importance for
729 European populations.

730 **3.1.1.7 Conclusions**

731 The Panel notes that mean intakes of SFAs, sodium and added/free sugars exceed the recommended
732 upper bounds of intake in the majority of European populations and subgroups thereof. The Panel
733 considers that excessive consumption of these nutrients is associated with adverse health effects, and
734 that a reduction in the intake of SFAs, sodium and added/free sugars is of public health importance for
735 European populations.

736 The Panel also notes that, owing to the high prevalence of overweight and obesity in Europe at all ages,
737 energy intake exceeds requirements for the maintenance of a normal body weight in the majority of
738 European populations. The Panel considers that excess energy intake leading to overweight and obesity
739 is associated with adverse health effects, and that a reduction of energy intake is of public health
740 importance for European populations. Although adverse health effects of diets high in TFAs are well
741 documented, mean intakes of TFAs in most European countries and population groups are at or below
742 recommended limits within the context of a nutritionally adequate diet. Moreover, the public health
743 importance of TFAs has been already addressed through the implementation of current European
744 legislation limiting the use of industrially produced TFAs in foods, which is expected to further reduce
745 intakes.

746 **3.1.2 Nutrients and non-nutrient components of food for which intakes might** 747 **be inadequate in relation to recommended levels in some population** 748 **groups and countries in Europe**

749 **3.1.2.1 Protein**

750 The human body requires dietary protein to support tissue growth and maintenance. The concept of
751 protein requirement includes both total nitrogen and indispensable amino acids. In this context, protein
752 is defined as total nitrogen x 6.25 and protein requirement is based on nitrogen content. In adults,
753 protein requirement can be measured individually using nitrogen balance, which is the difference
754 between nitrogen intake and the amount lost in urine, faeces, via the skin and other routes. In healthy
755 adults who are in energy balance, the protein requirement (maintenance requirement) is defined as
756 the amount of dietary protein sufficient to achieve zero nitrogen balance (EFSA NDA Panel, 2012a).

757 Animals and plants are the main dietary sources of protein. Most animal sources (meat, fish, egg, milk
758 and dairy products) provide high-quality protein, i.e. with high digestibility and optimal indispensable
759 amino acid composition (i.e. high biological value) for human needs. The indispensable amino acid
760 content of plant proteins (grains and grain-based products, legumes, and nuts) and/or their digestibility
761 is usually lower. However, the combination of different plant sources of protein (e.g. grains and
762 legumes) may result in an adequate indispensable amino acid intake for humans (EFSA NDA Panel,
763 2012a).

764 A meta-analysis of available data on nitrogen balance as a function of nitrogen intake (Rand et al.,
765 2003) was used to estimate the average requirement for protein in adults and children as 105 mg N
766 (or 0.66 g high quality protein) per kg body weight per day, with the 97.5th percentile being at 133 mg
767 N (or 0.83 g high quality protein) per kg body weight per day. Thus, an intake of 0.83 g of high-quality
768 protein/kg per day (e.g. 58 g/day for a 70-kg individual) was considered sufficient to cover the protein
769 requirements of 97.5% of the general adult population. This PRI derived by EFSA can be applied to
770 usual mixed diets in Europe, which are likely to contain sufficient amounts of all indispensable amino
771 acids (EFSA NDA Panel, 2012a).

772 Protein intakes above the level required to achieve nitrogen balance (i.e. the PRI) have no beneficial
773 effects on muscle mass or function at any age. The scientific evidence for the adverse health effects of
774 high protein intakes reported in the literature (i.e. in relation to body weight control, glucose
775 homeostasis, bone health or kidney function) did not allow to derive a UL for dietary protein (EFSA NDA
776 Panel, 2012a).

777 Dietary surveys in Europe suggest that average protein intakes in the European adult population (i.e.
778 ranging between 67 and 114 g/day in men and between 59 and 102 g/day in women) are mostly above
779 the PRI. Dietary surveys also indicate that protein intakes are at, or more often above, the PRI in infants
780 >6 months of age (EFSA NDA Panel, 2017), in children, and during pregnancy and lactation (EFSA NDA
781 Panel, 2012a).

782 The Panel notes that average protein intakes in Europe are above the PRI in most population groups
783 and countries, and that no beneficial effects on muscle mass or function can be expected from
784 increasing protein intakes further.

785 **3.1.2.2 EPA and DHA**

786 EPA and DHA are n-3 LC-PUFAs, i.e. n-3 PUFAs with ≥ 20 carbon atoms. EPA can be transformed to
787 eicosanoids. These include prostaglandins, prostacyclins and leukotrienes, which are involved in the
788 regulation of blood pressure, renal function, blood coagulation, inflammatory and immunological
789 reactions and other processes. DHA is a component of structural lipids of membranes. It is mostly found
790 in phospholipids in the nervous tissue and the retina. Large amounts are accumulated in the developing
791 brain, particularly during the first two years of life (EFSA NDA Panel, 2010c).

792 A meta-analysis of RCTs in adults without existing CVD comparing high with low n-3 LC PUFA
793 consumption, showed a small but statistically significant reduction in the risk of CVD including CHD
794 mortality and in the risk of CHD events with moderate to low certainty in the evidence (Abdelhamid et
795 al., 2020). Prospective cohort studies also indicate that fish consumption decreases the risk of CVD,
796 and particularly the risk of CHD mortality and sudden cardiac death, in healthy individuals (EFSA NDA
797 Panel, 2010c, 2014c). These associations have also been observed when n-3 LC-PUFAs are used as the
798 exposure variable instead of fish and appear to be dose dependent up to about 250 mg of EPA and
799 DHA per day, i.e. 1-2 servings of oily fish per week (EFSA NDA Panel, 2010e, 2014c).

800 There are several mechanisms by which the intake of EPA and DHA from fish and fish oil could reduce
801 CVD risk. EPA and DHA have a well-established antiarrhythmic effect and decrease blood triglycerides,
802 blood pressure, heart rate, and platelet aggregation in a dose-response manner. The shape of these
803 doses-response curves and their time course, however, are highly variable, as well as the relative
804 contribution of each of these factors to CVD risk prevention. At the levels of intake observed in European
805 diets (in the milligram/day range), the physiological effects that are most likely to account for clinical
806 cardiovascular benefits, particularly regarding fatal CHD and sudden cardiac death prevention, are a)
807 the modulation of myocardial sodium and calcium ion channels, reducing susceptibility to ischemia-
808 induced arrhythmia, and b) improved myocardial efficiency as a result of reduced heart rate, lower
809 systemic vascular resistance, and improved diastolic filling (Mozaffarian and Rimm, 2006; Mozaffarian
810 and Wu, 2011; Rimm et al., 2018).

811 The AI for adults for the combination of EPA and DHA of 250 mg/day was set by the NDA Panel based
812 on studies on fish consumption and primary prevention of CVD. The same AI was set for children aged
813 2 years and above. For infants >6 months and young children up to 2 years, an AI for DHA of 100
814 mg/day was derived based on the effect of this fatty acid on visual function in the complementary
815 feeding period (EFSA NDA Panel, 2010c).

816 Sources of EPA and DHA are almost exclusively foods of marine origin, mainly oily fish and derived
817 products.

818 Representative dietary intake estimates of EPA and DHA in Europe are sparse. In 2012 (EFSA NDA
819 Panel, 2012b), the intake data available (from 4 or 5 European countries depending on the fatty acid)
820 came from various publications using different dietary assessment methods, food composition
821 databases and age cut-offs. Mean daily intakes in adults from food only (i.e. excluding food
822 supplements) were between 50 mg/day and 150 mg/day for EPA and between 131 mg/day and 273
823 mg/day for DHA. In 2014 (EFSA NDA Panel, 2014c), harmonised nutrient intake data from seafood
824 (including EPA and DHA combined) were calculated for the five European countries with the highest
825 percentage of seafood consumed specified at species level in dietary surveys, using the EFSA food

826 composition and consumption databases. Mean daily intakes of EPA and DHA in adults ranged from
827 122 to 585 mg/day, with high variability across countries depending on the percentage of fish
828 consumers. Mozaffarian et al. (2017) reported median intakes of EPA and DHA from fish between 89
829 mg/day and 563 mg/day in prospective cohort studies conducted in five European countries, with the
830 highest intakes being found mostly in northern European countries.

831 The Panel notes that harmonised EPA and DHA intake data across European countries and population
832 groups are scarce and that intakes may vary widely across countries depending on the intake of
833 fish/seafood and products thereof.

834 The average consumption of fish flesh and processed fish and seafood per day in adults and adolescents
835 (consumers and non-consumers) in 21 EU Member States as reported in the EFSA Comprehensive Food
836 Consumption Database ranges from around 7 to 58 g/day, the wide range also reflecting the varying
837 percentages of individuals who consumed fish on the days of the surveys. As the data are mostly based
838 on 24-h recalls and dietary records with 2-3 replicates²⁹, the percentage of individuals never consuming
839 fish in EU Member States cannot be reliably estimated. The recommendations for fish consumption in
840 FBDGs of EU Member States differ and range from 100 to 500 g/week. Even though in the majority of
841 surveys the mean weekly consumption of fish flesh and processed fish and seafood reaches 100 g,
842 comparisons to national recommendations indicate that mean intakes are below those
843 recommendations in all or some subpopulations of adults and adolescents in Austria (pregnant women
844 and adolescents only), the Czech Republic, Denmark, Germany, Greece, Hungary, Ireland (adults, but
845 not in the elderly or very elderly), Italy (very elderly only), Latvia (pregnant women only), Romania and
846 Sweden (adolescents only). The Panel notes that the available data suggest that fish consumption in
847 some EU Member States is below national recommendations.

848 The Panel considers that intakes of EPA and DHA may be below the AI in European countries with low
849 fish consumption.

850 The Panel considers that intakes of EPA and DHA may be inadequate for primary CVD risk reduction in
851 Member States with low consumption of fish/seafood and products thereof.

852 3.1.2.3 Dietary fibre

853 Dietary fibre has been defined in several ways for risk assessment and management purposes. In
854 EFSA's Scientific Opinion on DRVs for carbohydrates and dietary fibre (EFSA NDA Panel, 2010b), dietary
855 fibre denotes all non-digestible carbohydrates. This includes non-starch polysaccharides, resistant
856 starches, resistant oligosaccharides with three or more monomeric units and other non-digestible, but
857 quantitatively minor components that are associated with the dietary fibre polysaccharides, especially
858 lignin. The most recent definitions of dietary fibre proposed at national and international level are quite
859 consistent, but differences exist regarding whether: a) associated substances (e.g. lignin) are explicitly
860 mentioned, b) the minimum number of monosaccharide units that are required to be included in the
861 definition, and c) the requirement, mainly for extracted, isolated, modified or synthetic carbohydrate
862 polymers, that they have a proven health benefit (Stephen et al., 2017). Most authorities provide non-
863 exhaustive lists of health benefits related to dietary fibre, the most common being in the areas of bowel
864 function, and of lipid and glucose metabolism. The definition of dietary fibre for regulatory purposes in
865 the EU is laid down in Regulation (EU) No 1169/2011.³⁰

866 The main characteristics that may mediate the health effects of dietary fibre include viscosity and the
867 capacity to form gels in the intestinal tract, fermentability in the colon, and water-holding capacity.

²⁹ Only in Ireland and Sweden four replicates were done and in Denmark seven.

³⁰ Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC and Commission Regulation (EC) No 608/2004. OJ L 304, 22.11.2011, p. 18–63.

868 Whole grain cereals, legumes, fruits and vegetables, and potatoes when eaten with the skin, are the
869 main sources of dietary fibre, but mushrooms, nuts and seeds also contain high amounts. In whole-
870 grain products, the lignified outer layers are the predominant dietary fibre source. Oats and barley
871 contain high concentrations of β -glucan, a water-soluble, viscous type of polysaccharide. Pectins are
872 the main type of dietary fibre in fruits and vegetables and have properties similar to β -glucan (EFSA
873 NDA Panel, 2010b).

874 Dietary fibre helps to maintain normal bowel function and alleviates constipation by decreasing colonic
875 transit time and increasing faecal mass (EFSA NDA Panel, 2010b; Portalatin and Winstead, 2012).
876 Dietary fibre increases stool bulk by enhancing the water-holding capacity of stools (Portalatin and
877 Winstead, 2012). Fermentable components of dietary fibre are metabolised by the microbiota, which
878 stimulates microbial growth and increases faecal bulk (Cummings, 2001).

879 The intake of dietary fibre as found in mixed diets has been inversely associated to the risk of developing
880 CVD and T2DM in prospective cohort studies (EFSA NDA Panel, 2010b). This is supported by the results
881 of recent meta-analyses investigating the relationship between dietary fibre intake and CHD
882 (Threapleton et al., 2013; McRae, 2017), stroke (Zhang et al., 2013; McRae, 2017), cardiovascular
883 mortality (McRae, 2017), and T2DM (Yao et al., 2014). The mechanisms by which dietary fibre could
884 affect CVD and T2DM risk are not fully elucidated but may depend on the characteristics of the different
885 fibre types. The viscosity and gel-forming capacity in the intestinal tract appear to influence glucose
886 and lipid metabolism. Viscous fibres have shown to delay carbohydrate absorption and decrease the
887 postprandial glycaemic responses to carbohydrate-rich meals. They could also lower blood total and
888 LDL-cholesterol concentrations (Bazzano, 2008) by increasing the viscosity of the gut content,
889 enhancing bile acid synthesis and excretion of bile acids and cholesterol in faeces (Ellegård and
890 Andersson, 2007; Wolever et al., 2010; Wang et al., 2017). Epidemiological evidence suggests a
891 beneficial effect of total dietary fibre on weight management (Koh-Banerjee et al., 2003; Du et al.,
892 2010).

893 In 2010, EFSA derived an AI of 25 g per day of dietary fibre from mixed diets (as AOAC fibre or
894 equivalent) that is compatible with an intestinal transit time of about two to three days and a
895 defaecation frequency of one per day and a faecal moisture of >70%, and may be considered adequate
896 for normal laxation in adults (EFSA NDA Panel, 2010b). Dietary fibre intake of 2 g per MJ was considered
897 adequate for normal laxation in children based on the dietary fibre intake that is adequate for normal
898 laxation in adults (25 g, equivalent to 2 to 3 g per MJ for daily energy intakes of 8 to 12 MJ) and taking
899 into account that energy intake relative to body size in children is higher than in adults. The effect of
900 dietary fibre on cardiometabolic risk is generally expected to occur at dietary fibre intakes above the AI
901 (EFSA NDA Panel, 2010b).

902 Average intakes of dietary fibre across European adult populations are in all surveys, except one, below
903 the AI of 25 g/day (data from national dietary surveys) (EFSA NDA Panel, 2010b). A more recent
904 compilation of national intake data compiled by the European Commission³¹ is mostly in line with this
905 observation. In children, the AI of 2 g/MJ was exceeded in around half of the surveys; in the other half,
906 mean intakes ranged from 1.7 to 1.9 g/MJ.

907 The Panel considers that adequate intake of dietary fibre contributes to maintaining normal bowel
908 function and normal laxation and contributes to reducing the risk of CVD and T2DM. Taking into account
909 that intakes of a majority of European adult populations are below recommendations, and that chronic
910 disease risk reduction could take place at intakes above those recommended for the maintenance of
911 normal bowel function, the Panel considers that an increase in dietary fibre intake is of public health
912 importance for European populations.

³¹ https://knowledge4policy.ec.europa.eu/health-promotion-knowledge-gateway/dietary-fibre-overview-3_en

913 **3.1.2.4 Potassium**

914 Potassium is an essential mineral and is required for normal cell function. It is the predominant
915 osmotically active intracellular element. It plays a major role in the transfer of water inside and outside
916 cells, assists in the regulation of the acid-base balance, and contributes to establishing a membrane
917 potential that supports electrical activity in nerve fibres and muscle cells (EFSA NDA Panel, 2016a).

918 Potassium intake has been reported to be associated with several health outcomes, particularly
919 cardiovascular endpoints. Adequate dietary potassium intake protects against developing hypertension
920 and improves blood pressure control in patients with hypertension, while inadequate potassium intake
921 may increase blood pressure (Aburto et al., 2013). Furthermore, there is consistent evidence from
922 observational cohort studies that potassium intakes below 3,500 mg (90 mmol)/day are associated with
923 a higher risk of stroke (Vinceti et al., 2016).

924 In 2016, EFSA established an AI for potassium of 3,500 mg (90 mmol)/day for adult men and women
925 based on the relationship between potassium intake, blood pressure and risk of stroke. For infants and
926 children, the AIs were extrapolated from the AI for adults by isometric scaling and including a growth
927 factor and range between 750 and 3,500 mg/day, depending on the age (EFSA NDA Panel, 2016a).
928 This was in line with WHO recommendations given in 2012 (WHO, 2012).

929 Potassium is present in all foods, with the highest contents in starchy roots or tubers, vegetables, fruits,
930 whole grains, dairy products, and coffee. In Europe, the main food groups contributing to potassium
931 intakes were starchy roots or tubers and products thereof, grains and grain-based products, milk and
932 dairy products, and vegetables and vegetable products and fruit and fruit products, including fruit and
933 vegetable juices (EFSA NDA Panel, 2016a). Substantial potassium losses may occur during food
934 processing and cooking (Barciela-Alonso and Bermejo-Barrera, 2015).

935 Mean dietary intakes of potassium in infants and children up to 10 years of age exceeded the AI, as
936 reviewed in EFSA NDA Panel (2016a) based on data derived from the EFSA Comprehensive Food
937 Consumption Database. In adults, average intakes of females were generally below the AI. Average
938 intakes of adult males were below the AI in around half of the surveys and age categories (EFSA NDA
939 Panel, 2016a).

940 Since adequate dietary intakes of potassium contribute to maintain blood pressure levels in the normal
941 range and to reduce the risk of stroke, and dietary intakes of potassium appear to be inadequate in the
942 majority of European adult populations, the Panel considers that an increase in potassium intakes is of
943 public health importance for European populations.

944 **3.1.2.5 Iodine**

945 Iodine is an essential nutrient, required as a structural and functional element of thyroid hormones.
946 Through the effects of these hormones, iodine has an important role in energy-yielding metabolism and
947 the expression of genes that control several physiological functions, including embryogenesis and
948 growth, and the development of neurological and cognitive functions (EFSA NDA Panel, 2014b).

949 The clinical effects of iodine deficiency are referred to as iodine deficiency disorders. Iodine deficiency
950 can lead to impaired thyroid function, goitre and hypothyroidism, and is associated with a decreased
951 fertility rate and increased infant mortality. Iodine deficiency is also linked to mental development
952 disorders in children, causing poor school performance and reduced work capacity (EFSA NDA Panel,
953 2014b).

954 In 2014, EFSA set an AI for iodine for adult men and women of 150 µg/day based on urinary iodine
955 excretion levels that have been associated with the lowest prevalence of goitre. For pregnant women,
956 an AI of 200 µg/day was derived. For infants aged 7–11 months and for children, AIs ranged between
957 70 µg/day and 130 µg/day (EFSA NDA Panel, 2014b).

958 Foods are very variable in their content of iodine. Good sources of iodine are marine products (such as
959 fish, crustaceans and bivalves), eggs, milk, and their derivatives, and iodised salt. It has to be, however,

960 noted that iodine content of milk and eggs is influenced by feeding practices (EFSA NDA Panel, 2014b).
961 Milk and dairy products are the main sources contributing to 25 - 70% of total daily iodine intake in
962 many European populations, depending on the amount of milk and dairy products consumed and their
963 iodine content (van der Reijden et al., 2017). Iodine intake is also related to the content of iodine salts
964 in soils, which is low in mountainous areas and river valleys prone to flooding (WHO, 2004).

965 Iodine fortification of salt has been implemented in 40 European countries, either as mandatory
966 fortification (13 countries) or voluntary fortification (16 countries), and is not regulated in the other
967 countries. The amount of iodine that is added varies from 10–75 mg/kg salt, but is mostly in the range
968 of 15–30 mg/kg (EFSA NDA Panel, 2014b). It is assumed that mandatory salt iodisation at 25 mg/kg
969 salt ensures adequate iodine intake in all population groups, including pregnant and lactating women
970 (Dold et al., 2018).

971 Iodine intake can be assessed by measuring urinary iodine concentration (UIC), as 90% of iodine
972 consumed is excreted in urine. The following criteria based on urinary iodine concentration in
973 populations have been suggested: median UIC <20 µg/L, severe iodine deficiency in the population;
974 median UIC 20-49 µg/L, moderate iodine deficiency; median UIC 50-99 µg/L, mild iodine deficiency;
975 median UIC 100-199 µg/L, adequate iodine intake. For pregnant women, a median UIC of <150 µg/L
976 reflects inadequate intakes in the population, owing to the higher iodine requirements during pregnancy
977 (WHO, 2004).

978 A UIC of 100 µg/L corresponds to an approximate iodine intake of 150 µg/day in adults.

979 In a recent study assessing iodine status in Europe based on data from 40 studies from 23 European
980 countries, median standardised³² UIC was <100 µg/L in 6.3% (i.e. 1 out of 16) studies in schoolchildren.
981 In adults, 53.8% (i.e. 7 out of 13) studies indicated iodine deficiency in the population with a median
982 standardised UIC <100 µg/L. Seven out of 11 (63.6%) studies in pregnant women had a median UIC
983 <150 µg/L (Ittermann et al., 2020).

984 The Panel considers that adequate dietary intakes of iodine are important for normal thyroid function
985 and prevent the incidence of iodine deficiency disorders. Inadequate iodine intakes that are observed
986 in some European countries and some sub-populations are mainly addressed by national policies in
987 Member States (see also Appendix B).

988 **3.1.2.6 Iron**

989 Iron is required for oxygen transport (as an essential component of haemoglobin), electron transfer,
990 oxidase activities and energy metabolism (EFSA NDA Panel, 2015b).

991 Often, iron deficiency anaemia (IDA) is used as a surrogate indicator of nutritional iron deficiency.
992 However, IDA may also have non-dietary causes, including conditions that cause blood loss or
993 malabsorption. IDA in infants and young children has been associated with impaired psychomotor
994 development and cognitive performance. However, much of the research performed on this outcome
995 is confounded by socio-economic factors and by the difficulties in standardising the outcome
996 measurements. In adults, impaired physical performance and an inefficient energy metabolism has
997 been observed (EFSA NDA Panel, 2015b).

998 In the Panel's Scientific Opinion on DRVs for iron (EFSA NDA Panel, 2015b), the PRI (AR) for iron has
999 been set at 11 (6) mg/day for adult men and post-menopausal women and at 16 (7) mg/day for pre-
1000 menopausal, pregnant and lactating women, by using a factorial approach. For children, age-specific
1001 values have been set and are stratified by age and sex subgroups, i.e. 11 (6) mg/day for infants 7-11
1002 months, 7 (5) mg/day for 1-6-year-olds. 11 (8) mg/day for 7-11-year-old children and 12-17-year-old
1003 boys and 13 (7) mg/day for 12-17-year-old females.

1004 Foods that contain relatively high concentrations of iron include meat, fish, cereals, beans, nuts, egg
1005 yolks, dark green vegetables, potatoes and fortified food products. The iron content of dairy products

³² Data of the individual studies were harmonised *a posteriori* using conversion formulas established by linear regression models

1006 and many fruits and vegetables is much lower. Bioavailability of iron from plant foods (non-haem iron)
1007 is generally much lower than that from animal (haem-iron) foods (due to a different absorption
1008 mechanism for non-haem iron versus haem-iron). The iron status in vegetarians and vegans has been
1009 reported to be markedly lower than the omnivorous counterparts in the population. However,
1010 absorption of elemental iron from plant sources can be enhanced by reducing agents present in food,
1011 most notably by the joint intake of vitamin C - this has also been acknowledged in previous EFSA
1012 Opinions (EFSA NDA Panel, 2009, 2015b).

1013 Dietary iron intakes have been estimated by EFSA using the EFSA Comprehensive Food Consumption
1014 Database, by selecting data from 13 dietary surveys from nine countries, i.e. Finland, France, Germany,
1015 Ireland, Italy, Latvia, the Netherlands, Sweden and the UK (EFSA NDA Panel, 2015b). Except for 7-11
1016 months-old infants, median iron intakes exceeded the AR in all population groups and surveys. In 7-
1017 11-months-old infants, median intakes were below the AR all four surveys available.

1018 Infants that are at particular risk of iron deficiency are exclusively breastfed infants >4 months of age
1019 born to mothers with a low iron status, with early umbilical cord clamping (< 1 min after birth), born
1020 preterm, born small-for-gestational age, or with a high growth velocity. These infants may benefit from
1021 the early introduction of complementary foods that are good sources of iron (EFSA NDA Panel, 2019a).
1022 The European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN)
1023 emphasises the importance of all infants receiving iron-rich complementary foods, owing to the high
1024 iron requirements during that life stage (Fewtrell et al., 2017).

1025 The Panel is aware that estimates of the percentage of the population that have inadequate iron intakes
1026 vary (Milman, 2019, 2020a; Milman, 2020b) and depend on the reference values that are chosen as
1027 comparator. Population groups that are commonly considered to have a higher risk of inadequate iron
1028 status are women of childbearing age, pregnant women and children, including certain exclusively
1029 breast-fed infants >4 months of age (see above). Generally, routine iron supplementation (of any
1030 population group) is not encouraged in Europe owing to the risk of overconsumption of iron in
1031 individuals with sufficient iron stores. Therefore, advice for supplementary intake is limited to individuals
1032 with clinically determined impaired iron stores (Brannon and Taylor, 2017).

1033 The Panel considers that low iron intakes are a risk factor for the development of IDA that is associated
1034 with adverse health effects. Inadequate iron intakes in infants at risk of iron deficiency are usually
1035 addressed by national nutrition policies in Member States by recommending feeding foods that are
1036 good sources of iron in the weaning period in line with the recommendations given by ESPGHAN.
1037 Inadequate iron intakes in other population subgroups are usually addressed through individual advice.

1038 **3.1.2.7 Calcium and vitamin D**

1039 Insufficient dietary supply of calcium leads to resorption of calcium from bone, causing a loss of bone
1040 mass that can result in osteopenia (i.e. lower than normal bone mineral density (BMD) and osteoporosis
1041 (EFSA NDA Panel, 2015a). Inadequate intakes of vitamin D lead to inefficient absorption of dietary
1042 calcium and phosphorus, and thus causes an impaired mineralisation of bone (EFSA NDA Panel, 2016b).
1043 However, also genotype and environmental and lifestyle factors other than calcium and vitamin D intake
1044 play key roles in the maintenance of BMD (EFSA NDA Panel, 2015a).

1045 Combined intakes of calcium and vitamin D at levels of or above 1,200 mg and 800 IU per day,
1046 respectively, have been associated with a reduction of the risk of osteoporotic fractures (EFSA, 2009;
1047 EFSA NDA Panel, 2010a). Also, there is evidence that intakes of vitamin D and calcium, as compared
1048 to calcium alone, reduce the risk of falling (EFSA NDA Panel, 2011a). More recent meta-analyses are in
1049 line with these findings (Yao et al., 2019; Thanapluetiwong et al., 2020).

1050 There is debate on the amount of calcium that is required to prevent osteoporosis. Willett et al. (2019)
1051 and WHO (2003) suggested that calcium intakes in adults of around 500 mg/day may already be
1052 sufficient to maintain bone health, based on the notion that in countries with a high fracture incidence,
1053 a minimum of 400-500 mg/day of calcium may be sufficient to prevent osteoporosis (WHO, 2003;

1054 Willett et al., 2019) and that increasing calcium intakes above this minimum level might not have a
1055 beneficial effect on the risk of fractures (Bischoff-Ferrari et al., 2007).

1056 However, DRVs for calcium indicate a PRI that is higher than 500 mg/day (DH, 1991; WHO/FAO, 2004;
1057 IoM, 2011; Nordic Council of Ministers, 2014; D-A-CH, 2015; EFSA NDA Panel, 2015a; ANSES, 2016;
1058 Health Council of the Netherlands, 2018).

1059 EFSA has proposed a PRI (AR) for young adults 18-24 years of age of 1,000 (860) mg/day and for
1060 adults ≥ 25 years of 950 (750) mg/day. For young children aged 1-3 years, the PRI (AR) for calcium
1061 has been set at 450 (390) mg/day, for children 4-10 years at 800 (680) mg/day, for adolescents 11-17
1062 years of age at 1,150 (960) mg/day (EFSA NDA Panel, 2015a).

1063 Unlike other vitamins, vitamin D₃ can be synthesised in the body following exposure to sunlight or
1064 artificial UV-B irradiation. Dietary intake is, however, essential when the endogenous synthesis is
1065 insufficient to cover requirements. Factors affecting the endogenous synthesis of vitamin D₃ include
1066 latitude, season, ozone layer and clouds (absorbing UV-B irradiation), surface characteristics (reflecting
1067 UV-B irradiation), time spent outdoors, use of sunscreen, clothing, skin colour and age. As these factors
1068 may vary considerably, DRVs have been derived based on the assumption that the endogenous vitamin
1069 D synthesis is minimal (EFSA NDA Panel, 2016b).

1070 Taking this into account, EFSA has set an AI for vitamin D for adults, including pregnant and lactating
1071 women, and children aged 1–17 years of 15 $\mu\text{g/day}$. For infants aged 7–11 months an AI of 10 $\mu\text{g/day}$
1072 was derived (EFSA NDA Panel, 2016b). These AIs can, however, mostly not, be achieved by dietary
1073 intakes alone. Intakes of around 16 $\mu\text{g/day}$ from food alone (i.e. somewhat higher than the AI) were
1074 only achieved in high consumers (95th percentile), according to published dietary intake data (EFSA
1075 NDA Panel, 2016b).

1076 The main contributors to calcium intake, as reviewed in EFSA NDA Panel (2015a), are milk and dairy
1077 products that are responsible for between 38 and 85% of the intake, followed by grains and grain-
1078 based products (2-35%), water and water-based beverages (1-18%) and vegetables and vegetable
1079 products (1-11%). Composite dishes and coffee, cocoa, tea and infusions also contribute up to 12% to
1080 the intake.

1081 Dietary sources of vitamin D are mostly fatty fish and eggs, food supplements and fortified foods. Small
1082 amounts are also provided by meat (Spiro and Buttriss, 2014).

1083 Calcium intake was estimated in the Panel's Scientific Opinion on DRVs for calcium (EFSA NDA Panel,
1084 2015a) by using data from the EFSA Comprehensive European Food Consumption Database. Data were
1085 available from 13 dietary surveys including nine countries (Finland, France, Germany, Ireland, Italy,
1086 Latvia (pregnant women), the Netherlands, Sweden and the UK). Comparison of the median calcium
1087 intake to the AR, showed that adolescents, in particular, are at risk of inadequate intakes. More than
1088 50% of this population (both males and females) in four out of five surveys (i.e. those of France,
1089 Germany, Italy and the Netherlands) had calcium intakes below the AR.

1090 The prevalence of inadequate vitamin D status, i.e. serum 25(OH)D concentrations of < 45 or 50 nmol/L,
1091 in Europe was reviewed by Spiro and Buttriss (2014). Studies from Austria, France, Germany, the
1092 Netherlands, Spain and Northern Europe showed that the prevalence of serum 25(OH)D concentrations
1093 of < 45 or 50 nmol/L ranged from about 28 to 67% in adults. For children, data from Austria showed
1094 that around 40% of 7-14-year-old children were below this cut-off and that 92% of 13-year old children
1095 from Denmark, Finland, Ireland and Poland did not reach serum 25(OH)D concentrations of 45-50
1096 nmol/L. Being at a higher risk of vitamin D inadequacy, the following population groups are often
1097 advised to take vitamin D supplements: infants and young children, pregnant and breast-feeding
1098 women, older people, individuals with low or no sun exposure, people with darker skin living in Europe
1099 (e.g. NICE, 2014; Rusińska et al., 2018).

1100 The Panel considers that adequate intakes of calcium and vitamin D are required for the maintenance
1101 of bone mass. A reduction in the risk of osteoporotic fractures and the risk of falling has only been

1102 evidenced beyond the PRI at intakes of and above 1,200 mg calcium and 800 IU vitamin D per day.
1103 The Panel notes that vitamin D status in European populations is inadequate in a large proportion of
1104 children and adults living in Europe and that population groups at particular risk of inadequate status
1105 are well known. The Panel also notes that dietary intakes of calcium may be inadequate in adolescents.
1106 Even though elderly may have sufficient calcium intakes compared with the DRVs, intakes may not be
1107 sufficient to reduce the risk of osteoporotic fractures and the risk of falling, especially if associated with
1108 a suboptimal vitamin D status.

1109 The Panel considers that whether an increase in calcium intake is beneficial may depend on the
1110 population group and that in some cases the recommended intake cannot be achieved through dietary
1111 modifications alone. The Panel also considers that vitamin D inadequacy in at-risk populations identified
1112 in the national context is ideally addressed by national policies in Member States.

1113 **3.1.2.8 Folate**

1114 Folate is a generic term used for a family of water-soluble organic compounds that belong to the group
1115 of B-vitamins. It is an essential micronutrient, required for the synthesis of ribo- and deoxyribonucleic
1116 acids (RNA and DNA), and consequently for cell division, and tissue growth, methylation reactions and
1117 amino acid metabolism (EFSA NDA Panel, 2014a).

1118 In folate deficiency, DNA replication and thus cell division may be impaired, leading to the production
1119 of large and immature macrocytic cells that can result in megaloblastic anaemia. It is well established
1120 that periconceptual folate supplementation is associated with a reduced risk of development of neural
1121 tube defects, a group of congenital malformations, in the developing fetus. As a consequence, women
1122 of childbearing age are advised to consume folic acid supplements in addition to food folate at a dose
1123 of 400 µg/day (IoM, 1998; EFSA NDA Panel, 2014a; D-A-CH, 2015; NHMRC, 2017; SACN, 2017).

1124 The EFSA NDA Panel (2014a) established an AI for folate for infants aged 7-11 months of 80 µg
1125 DFE³³/day. For children and adolescents, PRIs were derived by using allometric scaling from the adult
1126 AR, and range from 120 to 330 µg DFE/day, respectively. For healthy adults, a PRI of 330 µg DFE/day
1127 was set based on the maintenance of adequate folate status. An AI of 600 µg DFE/day was proposed
1128 for pregnancy. This value does not include the advice to consume folic acid supplements
1129 periconceptionally. For lactating women, a PRI of 500 µg DFE/day was set.

1130 The main sources of naturally occurring food folates are dark green leafy vegetables, legumes and rice.
1131 From animal sources, beef liver and crabs are particularly high in folate. Fortified foods, such as
1132 breakfast cereals, are the main contributors to the overall dietary intake of folic acid (EFSA NDA Panel,
1133 2014a). Dietary intake of folate was estimated by the Panel in its Opinion on DRVs for folate (EFSA
1134 NDA Panel, 2014a), based on national dietary surveys from the Netherlands, Ireland and Germany, the
1135 only surveys available at the time expressing intakes as DFEs, even though the way in which DFEs were
1136 computed was heterogeneous among them. The Panel notes that data on folate intake in Europe
1137 expressed as DFE are insufficient and do not allow conclusions to be drawn on the adequacy of intake
1138 in European populations.

1139 The Panel considers that the main public health concern in relation to folate intakes is the
1140 periconceptual folate intake of women of childbearing age, that is mainly addressed by national
1141 policies in Member States (see also Appendix B).

1142 **3.1.2.9 Conclusions**

1143 The Panel concludes that intakes of dietary fibre and potassium are inadequate in a majority of
1144 European adult populations. An increase in the intake of these nutrients is of public health importance
1145 owing to the adverse health effects that are caused by inadequate intakes of these nutrients. An
1146 increase in intake may be achieved through modification of the habitual diet. The Panel also considers

³³ DFE: dietary folate equivalents. For combined intakes of food folate and folic acid, DFEs can be computed as follows: µg DFE = µg food folate + (1.7 × µg folic acid)

1147 that intakes of EPA and DHA may be inadequate for primary CVD risk prevention in Member States with
1148 low consumption of fish/seafood and products thereof.

1149 The Panel notes that intakes of calcium, vitamin D, folate, iodine and iron may also be inadequate in
1150 certain subgroups of European populations. An increase in the intake of these nutrients is important for
1151 such subgroups of the population only, and adequate intakes may not always be achieved through
1152 modification of the habitual diet. Inadequate intakes of these nutrients are usually addressed by
1153 national nutrition policies in Member States and/or individual advice.

1154 The Panel also notes that, even if dietary protein is required to support tissue growth during childhood
1155 and adolescence and maintain muscle mass and function during adulthood and in the elderly, average
1156 protein intakes in Europe are above the PRI in most population groups and countries.

1157 **3.2 Food groups which have important roles in diets of European** 1158 **populations and subgroups thereof**

1159 **3.2.1 Role of food groups in European diets as addressed in food-based dietary** 1160 **guidelines of EU Member States**

1161 Twenty-eight FBDGs from 27 EU Member States were considered in this Opinion, as compiled by
1162 Wollgast et al. (2018). Belgium had two FBDGs, one for Flanders and one for Wallonia.

1163 **Starchy foods:** Starchy foods provide complex carbohydrates. When consumed in the form of whole
1164 grain products, they are also a good source of dietary fibre, B-vitamins, tocopherols and folate. This
1165 food group in FBDGs of European countries comprises mainly cereals and cereal-derived products, such
1166 as bread, pasta, rice, couscous or bulgur, and potatoes. However, it also includes products that may
1167 contain considerable amounts of sugars, fat, SFAs and/or salt, such as some breakfast cereals, fine
1168 bakery wares, fried products, snacks or some breads.

1169 Generally, FBDGs recommend eating starchy foods several times per day with an emphasis on whole
1170 grain products, on choosing products low in SFAs, sugars and/or sodium and on reducing consumption
1171 of fried products.

1172 The FoodEx 2 term names (level 1) in EFSA's Comprehensive Food Consumption Database associated
1173 with starchy foods are 'grains and grain-based products' and 'starchy roots and tubers and primary
1174 derivatives thereof'.

1175 **Fruits and vegetables, including juices:** Fruits and vegetables are sources of vitamins, minerals
1176 and dietary fibre. FBDGs stress the importance of consuming a variety of fruits and vegetables every
1177 day. However, processing may alter the nutritional properties. For example, juicing leads to a reduction
1178 in dietary fibre content and drying to a concentration of the natural sugar content. Also, sugar could
1179 be added during processing, such as in canned fruits with syrup, compotes, marmalades or jams. FBDGs
1180 are nevertheless not homogeneous in their recommendations regarding the consumption of food
1181 products within this group. For example, fruit juices are considered equivalent to a portion of fruit in
1182 one country and as sugar-sweetened beverages in another. Most countries, however, recommend
1183 restricting the consumption of **fruit juice** to about one serving per day or suggest preferring fresh fruit
1184 over juice. A few countries also suggest limiting the intake of **dried fruits** or **canned fruits** or advise
1185 the consumption of canned fruits in natural juice rather than syrups. Some processed vegetables may
1186 also contain significant amounts of added sodium.

1187 The FoodEx 2 term names (level 1) associated with fruits and vegetables are 'fruit and fruit products'
1188 and 'vegetable and vegetable products'. Fruit and vegetable juices and nectars are covered under 'fruit
1189 and vegetable juices and nectars (including concentrates)' also at level 1.

1190 **Legumes and pulses:** Legumes and pulses provide carbohydrates, dietary fibre and protein and are
1191 also rich in micronutrients. Recommendations in FBDGs to consume legumes span from consumption
1192 of 1-2 times per week to up to 3-4 times per week. The consumption of legumes and pulses is

1193 specifically encouraged in six FBDGs and in another 10 the substitution of meat with legumes and
1194 pulses is recommended. Canned legumes and pulses may contain significant amounts of added sodium.

1195 The associated FoodEx 2 term name is 'legumes' at level 2, nested within 'legumes, nuts, oilseeds and
1196 spices' (level 1).

1197 **Milk and dairy products:** Milk and dairy products are important contributors to the intake of protein,
1198 calcium, riboflavin, vitamin B₁₂ and iodine. They may, however, also contribute to SFA intake (depending
1199 on the fat content) and to added sodium or added sugar intake. FBDGs of EU Member States are
1200 consistent in recommending daily consumption of skimmed and semi-skimmed milk, low-fat yoghurt,
1201 sour milk products or similar and low-fat cheeses. In some cases, recommendations are made to choose
1202 cheeses low in salt and dairy without added sugar.

1203 The associated FoodEx 2 term name (level 1) is 'milk and dairy products'.

1204 **Meat and meat products (including offal):** Meat is a good source of high-quality protein, iron,
1205 zinc, some vitamins (e.g. vitamin A and D) and MUFAs. Meat and meat products may, however,
1206 contribute significantly to the intake of SFAs and added sodium in case of processed meat. Most FBDGs
1207 recommend limiting meat intake typically to around 300-600 g per week, mainly choosing lean meats,
1208 and not eating meat every day. Some FBDGs specifically suggest reducing consumption of red meat
1209 and processed meat. As alternatives to meat, fish, eggs, pulses and products thereof, including tofu,
1210 and mycoprotein-based foods as well as seitan are mentioned.

1211 The associated FoodEx 2 term name (level 1) is 'meat and meat products'. Meat substitutes are not
1212 included in this category.

1213 **Fish and shellfish including products thereof:** Fish, depending on the species, is a significant
1214 contributor to n-3 LC-PUFAs, iodine and vitamin D intake. Some processed fish products may be high
1215 in sodium. Regular fish consumption is recommended in all FBDGs of Member States, ranging from 1
1216 to 4 times per week, serving sizes ranging from 30 g to 200 g, but being mostly 100-150 g. Five Member
1217 States suggest eating fatty fish, one Member State low-to-medium fat fish and four Member States
1218 indicate that it is important to vary species and fishing locations.

1219 The associated FoodEx 2 term names at level 2 are 'fish (meat)', 'fish offal' and 'fish and seafood
1220 processed' nested under 'fish, seafood, amphibians, reptiles and invertebrates' at level 1. 'Fish
1221 processed' is found as level 3 under 'Fish and seafood processed'.

1222 **Oils and fats:** Most vegetable oils are rich in MUFAs and PUFAs. Palm oil, palm kernel oil, coconut oil
1223 and animal fats are high in SFAs. Hydrogenated oils may be a source of TFAs. Generally, FBDGs
1224 recommend the consumption of vegetable oils high in unsaturated fatty acids and to limit consumption
1225 of SFAs.

1226 The FoodEx 2 term name at level 1 is 'animal and vegetable fats and oils and primary derivatives
1227 thereof'

1228 **Nuts and seeds:** Nuts and seeds are good sources of unsaturated fatty acids (including essential fatty
1229 acids), protein, dietary fibre, vitamins and minerals (e.g. calcium, magnesium, iron, zinc). Most FBDGs
1230 contain recommendations for consumption of unsalted and unsweetened nuts and seeds (without extra
1231 fat) that range from daily intake to consumption of 2-3 times per week, serving sizes ranging from 10
1232 to 40 g, mostly being 15 to 25 g.

1233 The associated FoodEx 2 term names at level 3 are 'treenuts' and 'oilseeds' nested under level 2
1234 'nuts, oilseeds and oilfruits' and level 1 'legumes, nuts, oilseeds and spices'.

1235 **Non-alcoholic beverages (excluding fruit and vegetable juices):** Non-alcoholic beverages are
1236 important for fluid intake. FBDGs of Member States recommend to drink between 1 and 3 L (mostly 1.5
1237 to 2 L), preferably water, every day. Most FBDGs recommend limiting the consumption of sugar-
1238 sweetened beverages, which can contribute to the intake of added sugars to a significant extent. Some

1239 Member States specifically advise moderating the intake of coffee, green and black tea, and other
1240 caffeine-containing beverages.

1241 The associated FoodEx 2 term names at level 1 are 'water and water-based beverages' and 'coffee
1242 cocoa tea and infusions'.

1243 **3.2.2 Food groups and health outcomes**

1244 Even though the effects of some individual nutrients and non-nutrient components of food on chronic
1245 disease risk are well established, as described in Section 3.1, these are usually found in foods and diets
1246 as complex mixtures, where synergistic or antagonistic effects may come into play. Food processing,
1247 including the preparation and cooking methods used at home, may also influence the health effects of
1248 individual foods.

1249 Diets high in fruits and non-starchy vegetables, whole grains, legumes, nuts and seeds, fish and
1250 shellfish, and unsaturated fat-rich vegetable oils, and low in refined starches, red meat, and processed
1251 foods and beverages with high sodium, added sugars and/or TFA content are associated with a lower
1252 risk of developing CVD, T2DM and some types of cancer in Western populations (Mozaffarian, 2016;
1253 Willett et al., 2019; USDA, 2020). The Mediterranean-style diet pattern (Davis et al., 2015) and the
1254 New Nordic diet-style pattern (Mithril et al., 2012; Mithril et al., 2013), also called Baltic Sea diet-style
1255 pattern, are good examples of such dietary patterns in Europe. The relationship between the
1256 consumption of other foods groups (e.g. dairy, butter, eggs, poultry) in mixed diets and chronic disease
1257 risk is less consistent (Mozaffarian, 2016).

1258 **Sources of protein**

1259 High quality protein is needed to ensure the growth of infants and young children, and to maintain lean
1260 body mass in the elderly. For people older than two years of age, however, a balanced plant-based diet
1261 can fulfil protein requirements (USDA, 2020). Meat, dairy, fish, eggs, legumes, and nuts are high in
1262 protein and often considered as alternatives to each other in dietary recommendations and FBDGs.
1263 However, they are also sources of other food constituents that may affect health, so that these protein
1264 sources may not be interchangeable as concerns their effect on health.

1265 Several systematic reviews and meta-analyses have investigated the association between red meat and
1266 processed meat consumption and the development of chronic metabolic diseases (Aune et al., 2009;
1267 Micha et al., 2010; Abete et al., 2014; Wang et al., 2016; Schwingshackl et al., 2017; Tian et al., 2017;
1268 Bechthold et al., 2019; Fan et al., 2019; Neuenschwander et al., 2019; Zeraatkar et al., 2019). In some
1269 articles, red meat was defined as fresh meat from beef, veal, lamb, or pork, including hamburgers and
1270 meatballs, and processed meat as any meat preserved by the addition of chemical preservatives,
1271 smoking, curing, or salting, such as bacon, salami, sausages, hot dogs, processed deli or luncheon
1272 meat (Abete et al. (2014). These meta-analyses consistently report a positive association between the
1273 consumption of processed meat and chronic metabolic disease outcomes, such as CHD, CVD mortality,
1274 myocardial infarction, stroke and T2DM as compared to other food sources, and particularly to other
1275 protein sources. The association between unprocessed red meat consumption and these outcomes was
1276 generally weaker and less consistent.

1277 In dose response meta-analyses conducted in the framework of these systematic reviews, the risk of
1278 disease was mostly increased at intakes of 50 and of 100-120 g/day for processed meat and
1279 unprocessed red meat, respectively.

1280 Based on colon cancer risk, processed meat and unprocessed red meat were classified by the
1281 International Agency for Research on Cancer (IARC)³⁴ as group 1 and 2A carcinogens to humans,
1282 respectively.

1283 Plausible mechanisms through which processed meat, and to a lesser extent of unprocessed red meat,
1284 could increase the risk of CVD, T2DM and certain types of cancer, include the intake of high amounts

³⁴ <https://monographs.iarc.who.int/wp-content/uploads/2018/06/mono114.pdf>

1285 of sodium and other preservatives (for processed meat only), haem iron and heat-induced carcinogens
1286 (process contaminants), as well as the unfavourable fatty acid profile (Al-Shaar et al., 2020; Papier et
1287 al., 2021).

1288 Consumption of dairy products and moderate consumption of eggs (up to one per day) appears to be
1289 unrelated to CVD mortality (Rong et al., 2013; Mozaffarian, 2016; Guo et al., 2017), although some
1290 meta-analyses have also reported inverse (i.e. beneficial) associations between total dairy consumption
1291 and CVD endpoints other than mortality (Drouin-Chartier et al., 2016; Chen et al., 2021). Fish intake
1292 (1-2 servings and up to 3-4 servings per week) significantly decreases CHD mortality in a dose-response
1293 manner (Zheng et al., 2012; EFSA NDA Panel, 2014c). It has recently been estimated that the risk of
1294 CVD mortality could be decreased by 4% per 20 g/day increment in fish consumption, and an optimal
1295 intake of 60 g fish/day for CHD mortality prevention has been suggested (Willett et al., 2019; Zhang et
1296 al., 2020). The intake of moderate amounts of nuts (30-60 g/day) has been shown to beneficially affect
1297 cardiometabolic risk factors in RCTs, including blood pressure, blood lipid profile and glucose
1298 metabolism, and to decrease the risk of fatal and non-fatal CVD, T2DM and overall mortality in
1299 prospective cohort studies in substitution of other food sources (Afshin et al., 2014; Aune et al., 2016a;
1300 Mayhew et al., 2016). Similar evidence is available for the consumption of legumes and CHD risk (Afshin
1301 et al., 2014), possibly owing to the blood LDL-cholesterol and blood pressure-lowering effects reported
1302 in RCTs.

1303 **Sources of digestible carbohydrates and dietary fibre**

1304 Carbohydrates are the largest source of energy in European diets. In 2010, the EFSA NDA Panel
1305 proposed an RI for digestible carbohydrates between 45 and 60 E% applicable to both adults and
1306 children older than one year of age (EFSA NDA Panel, 2010b). Major sources of complex carbohydrates
1307 in European diets are cereals and potatoes. Whole grain cereals and potatoes, if eaten with the skin,
1308 are also good sources of dietary fibre.

1309 Diets high in whole grains have been associated with lower mortality from all causes, CVD and cancer
1310 in prospective cohort studies. In a dose response meta-analysis, these associations were monotonic,
1311 showing a decrease in risk for total, CVD, and cancer mortality of about 7, 9 and 5%, respectively, for
1312 each serving (16 g) increase in whole grain intake per day (Zong et al., 2016).

1313 Fruits and vegetables are also good sources of carbohydrates (naturally occurring sugars), vitamins,
1314 minerals, phytochemicals and dietary fibre. Meta-analyses from prospective cohort studies have
1315 consistently reported a lower risk of all-cause mortality, and particularly CVD mortality, associated with
1316 the consumption of fruits and vegetables (Wang et al., 2014; Aune et al., 2017; Wang et al., 2021).
1317 For each additional serving of fruits or vegetables per day (about 80 g/day), the risk appears to decrease
1318 monotonically by about 3-5% (depending on the analysis) up to five servings per day (or two servings
1319 of fruits and three of vegetables). The relationship with cancer risk has been less consistent. While
1320 Wang et al. (2014) report no association and a prospective analysis of the European Prospective
1321 Investigation into Cancer and Nutrition (EPIC) cohort only shows a very small and inconsistent risk
1322 reduction at high intakes (Boffetta et al., 2010), more recent meta-analyses including higher number
1323 of studies, participants and events, consistently show lower risk of cancer associated with the
1324 consumption of fruits and vegetables (or fruits and vegetables separately) up to about five servings per
1325 day (Aune et al., 2017; Wang et al., 2021).

1326 Potatoes are starchy vegetables widely consumed in European diets. They contain high amounts of
1327 potassium, are a good source of dietary fibre if eaten with the skin, and provide vitamins C and B₆,
1328 among other nutrients. The relationship between the intake of potatoes and chronic disease risk,
1329 particularly T2DM, has been systematically investigated because, as is the case with other refined
1330 starches, such as white bread or white rice, they contain high amounts of readily available
1331 carbohydrates. Recent systematic reviews and meta-analyses show positive (i.e. unfavourable) dose-
1332 response relationships between the consumption of potatoes and diabetes risk in Western populations,
1333 but the strength of the association differs depending on the way potatoes are prepared. Either no or a
1334 mostly modest increase in T2DM risk has been reported for high vs. low consumers of
1335 boiled/baked/mashed potatoes (Borch et al., 2016; Zhang et al., 2018; Quan et al., 2020; Guo et al.,

1336 2021). Conversely, the association between French fries and diabetes risk is consistent across
1337 systematic reviews, and is from 2 to 6 times stronger than for boiled/baked/mashed potatoes, possibly
1338 because of the strong relationship observed also in relation to weight gain (Borch et al., 2016; Zhang
1339 et al., 2018; Quan et al., 2020; Guo et al., 2021).

1340 **Oils and fats**

1341 Fats are commonly used for cooking and dressing worldwide. Animal (such as butter and lard) and
1342 vegetable (such as oils, margarines and shortenings) fats contain mixtures of SFAs, MUFAs and PUFAs
1343 in different proportions, but also other nutrients (e.g. β -carotene and vitamin D) and non-nutrient
1344 components (e.g. polyphenols (EFSA NDA Panel, 2011c)) with potential health effects. While the relative
1345 effect of individual fat sources on blood cholesterol concentrations may be predicted by their fatty acid
1346 composition, as discussed in Sections 3.1.1.2 and 3.1.2.2, other health effects that may be related to
1347 the consumption of the fat source itself could be more difficult to anticipate.

1348 As expected by their fatty acid profile, consumption of vegetable oils high in n-3 and n-6 PUFAs (e.g.
1349 sunflower oil, corn oil, soybean oil) in replacement of SFA-rich foods decreases blood LDL-cholesterol
1350 concentrations and CHD risk (Mozaffarian et al., 2010). Despite the more neutral effect of MUFAs (such
1351 as oleic acid in olive oil and rapeseed oil) compared with PUFAs on the blood lipid profile when replacing
1352 SFAs, replacement of dairy fat (butter) by rapeseed oil for cooking may partly explain the effect of
1353 dietary interventions in Northern Europe on the reduction of blood cholesterol concentrations and CHD
1354 mortality at national level (Puska and Ståhl, 2010). Plant-based Mediterranean-type diets rich in olive
1355 oil have also been traditionally associated with low CVD risk in observational and intervention studies
1356 (Rosato et al., 2019). Some vegetable oils that are high in SFAs, like palm oil or coconut oil, are expected
1357 to increase LDL-cholesterol, although long-term studies on chronic disease risk related to the
1358 consumption of these oils are lacking.

1359 **3.2.3 Conclusions**

1360 Food groups with important and specific dietary roles in European diets include starchy foods (cereals
1361 and potatoes), fruits and vegetables, legumes and pulses, milk and dairy products, meat and meat
1362 products, fish and shellfish and products thereof, nuts and seeds, and non-alcoholic beverages, as
1363 recognised in FBDGs in Member States. However, the dietary roles of these food groups and their
1364 relative contribution to the overall diet may vary across individual countries owing to the variability of
1365 dietary habits and traditions.

1366 Dietary recommendations made in FBDGs by EU Member States reflect the available evidence on the
1367 consumption of certain food groups and their relationship with chronic disease risk, as reviewed in
1368 Section 3.2.2. Emphasis is put on increasing the consumption of whole grains, fruits and vegetables (in
1369 a wide variety), nuts and seeds, fish and water. Specific food products within some of these food
1370 categories that are high in SFAs, sugars and/or sodium owing to food processing are generally
1371 discouraged. Most FBDGs recommend limiting meat intake, some suggesting specifically the reduction
1372 of unprocessed red and processed meat consumption. FBDGs encourage regular consumption of fat-
1373 reduced milk and dairy products, the consumption of legumes and pulses instead of meat, and the
1374 consumption of vegetable oils rich in *cis*-MUFAs and *cis*-PUFAs instead of fats high in SFAs. The Panel
1375 notes that food groups with an important role in the diet of European populations and subgroups
1376 thereof have been identified by Member States in FBDGs. The Panel also notes that FBDGs also
1377 distinguish between different products within these food groups based on their potential to influence,
1378 beneficially or adversely, the overall dietary balance for certain nutrients.

1379 **3.3 Choice of nutrients and non-nutrient components of foods for** 1380 **nutrient-profiling**

1381 The choice of nutrients and non-nutrient components of food to set nutrient profiling models, for the
1382 purpose of restricting claims on foods and the purpose of FOP labelling, should be driven by their public
1383 health importance for EU populations, as discussed in Section 3.1.

1384 Dietary intakes of SFAs, sodium and added/free sugars on one hand, and dietary fibre on the other,
1385 are respectively above and below current recommendations in a majority of European populations, and
1386 could be considered for inclusion in nutrient profiling models based on their public health importance
1387 for European populations.

1388 Total sugars can be used as a proxy for added/free sugars in category-based nutrient profiling models
1389 because added/free sugars are the most variable fraction of total sugars between food products within
1390 a given food category. This also applies to food categories containing sugars but no added/free sugars
1391 in the unprocessed version (e.g. fruits and vegetables, milk and dairy products). Total sugars may not
1392 be equally suitable for nutrient profiling models to be applied across the board.

1393 In self-selected diets under isocaloric conditions, a reduction in the intake of an energy-providing
1394 nutrient is accompanied by the increase in the intake of another. This substitution is of particular
1395 importance when it comes to a reduction in the intake of SFAs. As described in Section 3.1.1.3, the
1396 health effects of lowering SFA intake depend on the type of energy-providing nutrient by which SFAs
1397 are replaced in the diet. The strongest beneficial effect on blood LDL-cholesterol concentrations and
1398 CHD risk is observed when mixtures of SFAs are replaced by mixtures of *cis*-PUFAs. The effects of
1399 replacing mixtures of SFAs by mixtures of *cis*-MUFAs are less pronounced and are even lower when
1400 SFAs are replaced by carbohydrates from whole grains. A replacement of SFAs with refined
1401 carbohydrates (e.g. sugars) has not been shown to have an effect (Visseren et al., 2021). The inclusion
1402 of SFAs and (added/free) sugars in a nutrient profiling model could mostly account for the fatty acid
1403 profile of foods and for the less favourable replacement of SFAs by refined carbohydrates.

1404 Energy could be included in nutrient profiling models because a decrease in energy intake is of public
1405 health importance for European populations owing to the high prevalence of overweight and obesity
1406 and the positive relationship between high energy dense-diets and risk of weight gain. The energy
1407 density of foods and of dairy-based beverages is mostly determined by their fat and water content,
1408 owing to their extreme energy values, while the energy density of non-alcoholic water-based beverages
1409 is mostly driven by their sugar content. In certain food groups (e.g. cereal products), dietary fibre may
1410 additionally contribute to the energy density of foods.

1411 Differences in water content may confound energy comparisons across foods and are bigger across
1412 food groups (e.g. between solid foods and beverages) than within food groups. This confounding is a
1413 great disadvantage when energy is used in nutrient profiling models intended for application across the
1414 board. Still, energy may be a suitable criterion if applied within food groups, where the water content
1415 is relatively consistent across products in the group.

1416 In food group/category-based nutrient profiling models, total fat could replace energy owing to its high
1417 energy density in most food groups, while the energy density of food groups with low or no fat content
1418 (e.g. water-based non-alcoholic beverages, jams and marmalades) may be well accounted for by the
1419 inclusion of (added/free) sugars in the model. However, total fat does not allow the discrimination of
1420 foods based on the nutritional quality of their fat content. Therefore, total fat cannot replace SFAs in
1421 nutrient profiling models, unless food products in a group are relatively homogeneous regarding their
1422 fat quality (e.g. milk and dairy products).

1423 In addition to sodium, for which intakes are above recommendations, other vitamins and minerals of
1424 public health importance could be considered, mostly because their intakes in European populations or
1425 certain subgroups thereof are lower than recommended. These include potassium, iron, calcium,
1426 vitamin D, folate and iodine (see Section 3.1.2). However, for all of these nutrients, except potassium,
1427 inadequate intakes are only observed in very specific subgroups of the population, in which dietary
1428 modifications alone may not be sufficient (or appropriate) to fulfil the nutrient requirements. Inadequate
1429 intakes of these nutrients are usually addressed by national nutrition policies in Member States and/or
1430 individual advice. That is not the case for potassium, for which dietary intakes appear to be inadequate
1431 in a majority of European adult populations and thus could be considered for inclusion in nutrient
1432 profiling models.

1433 Some nutrients and non-nutrient components may be included in nutrient profiling models for reasons
1434 other than their public health importance to allow for a better discrimination of foods within the same
1435 food category. In this context, n-3 LC-PUFAs, for which fish and shellfish including products thereof are
1436 almost the only dietary source, could be included in nutrient profiling models owing to the large
1437 differences among fish species regarding the content of these fatty acids. This is despite current
1438 uncertainties on whether intakes may be below current recommendations in some EU Member States.

1439 Another consideration in the choice of the nutrients and non-nutrient components to be included in a
1440 nutrient profiling system is the feasibility of the nutrient profile in practice. The larger the number of
1441 components included, the more complex the nutrient profile becomes in its application.

1442 **4 Conclusions**

1443 The Panel concludes that:

- 1444 • food groups with important and specific dietary roles in European diets include starchy foods
1445 (cereals and potatoes), fruits and vegetables, legumes and pulses, milk and dairy products,
1446 meat and meat products, fish and shellfish and products thereof, nuts and seeds, and non-
1447 alcoholic beverages, as recognised in FBDGs in Member States. The dietary roles of these food
1448 groups and their relative contribution to the overall diet may vary across individual countries
1449 owing to the variability of dietary habits and traditions.
- 1450 • dietary recommendations made in FBDGs by EU Member States reflect the available evidence
1451 on the consumption of certain food groups and their relationship with chronic disease risk.
1452 Consumption of whole grains, fruits and vegetables, nuts and seeds, fat-reduced milk and dairy
1453 products, fish and water is encouraged, whereas food products high in SFAs, sugars and/or
1454 sodium owing to food processing are generally discouraged, even within these food categories.
1455 FBDGs also encourage regular consumption of legumes and pulses instead of meat (particularly
1456 red meat and processed meat), and the consumption of vegetable oils rich in *cis*-MUFAs and
1457 *cis*-PUFAs instead of fats high in SFAs.
- 1458 • dietary intakes of SFAs, sodium and added/free sugars are above current dietary
1459 recommendations in a majority of European populations; excess intakes of these nutrients are
1460 associated with adverse health effects and therefore they could be considered for inclusion in
1461 nutrient profiling models based on their public health importance for European populations;
- 1462 • energy could be included in nutrient profiling models because a decrease in energy intake is of
1463 public health importance for European populations; in food group/category-based nutrient
1464 profiling models, total fat could replace energy owing to its high energy density in most food
1465 groups, while the energy density of food groups with low or no fat content (e.g. water-based
1466 non-alcoholic beverages, jams and marmalades) may be well accounted for by the inclusion of
1467 (added/free) sugars in the model.
- 1468 • intakes of dietary fibre and potassium are below current dietary recommendations in a majority
1469 of European adult populations; inadequate intakes of dietary fibre and potassium are associated
1470 with adverse health effects and therefore dietary fibre and potassium could be considered for
1471 inclusion in nutrient profiling models based on their public health importance for European
1472 populations;
- 1473 • dietary intakes of iron, calcium, vitamin D, folate and iodine are below current dietary
1474 recommendations in specific sub-groups of European populations only in which dietary
1475 modifications alone may not be sufficient (or appropriate) to fulfil the nutrient requirements;
1476 inadequate intakes of these nutrients are usually addressed by national nutrition policies in
1477 Member States and/or individual advice;
- 1478 • nutrients and non-nutrient components of food may be included in nutrient profiling models for
1479 reasons other than their public health importance to allow for a better discrimination of foods
1480 within the same food category.

1481 **5 References**

- 1482 Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KH, Summerbell CD,
1483 Worthington HV, Song F and Hooper L, 2020. Omega-3 fatty acids for the primary and secondary
1484 prevention of cardiovascular disease. *Cochrane Database Syst Rev*, 3:Cd003177. doi:
1485 10.1002/14651858.CD003177.pub5
- 1486 Abete I, Romaguera D, Vieira AR, Lopez de Munain A and Norat T, 2014. Association between total,
1487 processed, red and white meat consumption and all-cause, CVD and IHD mortality: a meta-analysis
1488 of cohort studies. *British Journal of Nutrition*, 112:762-775. doi: 10.1017/S000711451400124X
- 1489 Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P and Cappuccio FP, 2013. Effect of increased
1490 potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses.
1491 *BMJ*, 346:f1378. doi: 10.1136/bmj.f1378
- 1492 Afshin A, Micha R, Khatibzadeh S and Mozaffarian D, 2014. Consumption of nuts and legumes and risk
1493 of incident ischemic heart disease, stroke, and diabetes: a systematic review and meta-analysis.
1494 *American Journal of Clinical Nutrition*, 100:278-288. doi: 10.3945/ajcn.113.076901
- 1495 Al-Shaar L, Satija A, Wang DD, Rimm EB, Smith-Warner SA, Stampfer MJ, Hu FB and Willett WC, 2020.
1496 Red meat intake and risk of coronary heart disease among US men: prospective cohort study. *BMJ*,
1497 371:m4141. doi: 10.1136/bmj.m4141
- 1498 American Diabetes Association, 2014. Diagnosis and classification of diabetes mellitus. *Diabetes Care*,
1499 37:S81-S90. doi: 10.2337/dc14-S081
- 1500 ANSES (Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail),
1501 2016. Actualisation des repères du PNNS: élaboration des références nutritionnelles. 196 pp.
- 1502 Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A,
1503 Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Munoz D, Smith SC, Jr., Virani SS, Williams
1504 KA, Sr., Yeboah J and Ziaeian B, 2019. 2019 ACC/AHA Guideline on the primary prevention of
1505 cardiovascular disease: A report of the American College of Cardiology/American Heart Association
1506 Task Force on Clinical Practice Guidelines. *Circulation*, 140:e596-e646. doi:
1507 10.1161/CIR.0000000000000678
- 1508 Astrup A, Magkos F, Bier DM, Brenna JT, de Oliveira Otto MC, Hill JO, King JC, Mente A, Ordovas JM,
1509 Volek JS, Yusuf S and Krauss RM, 2020. Saturated fats and health: A reassessment and proposal for
1510 food-based recommendations: JACC state-of-the-art review. *Journal of the American College of*
1511 *Cardiology*, 76:844-857. doi: 10.1016/j.jacc.2020.05.077
- 1512 Aune D, Giovannucci E, Boffetta P, Fadnes LT, Keum N, Norat T, Greenwood DC, Riboli E, Vatten LJ
1513 and Tonstad S, 2017. Fruit and vegetable intake and the risk of cardiovascular disease, total cancer
1514 and all-cause mortality-a systematic review and dose-response meta-analysis of prospective studies.
1515 *International Journal of Epidemiology*, 46:1029-1056. doi: 10.1093/ije/dyw319
- 1516 Aune D, Keum N, Giovannucci E, Fadnes LT, Boffetta P, Greenwood DC, Tonstad S, Vatten LJ, Riboli E
1517 and Norat T, 2016a. Nut consumption and risk of cardiovascular disease, total cancer, all-cause and
1518 cause-specific mortality: a systematic review and dose-response meta-analysis of prospective
1519 studies. *BMC Medical*, 14:207. doi: 10.1186/s12916-016-0730-3
- 1520 Aune D, Sen A, Prasad M, Norat T, Janszky I, Tonstad S, Romundstad P and Vatten LJ, 2016b. BMI and
1521 all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort
1522 studies with 3.74 million deaths among 30.3 million participants. *BMJ*, 353:i2156. doi:
1523 10.1136/bmj.i2156
- 1524 Aune D, Ursin G and Veierød MB, 2009. Meat consumption and the risk of type 2 diabetes: a systematic
1525 review and meta-analysis of cohort studies. *Diabetologia*, 52:2277-2287. doi: 10.1007/s00125-009-
1526 1481-x
- 1527 Barciela-Alonso MC and Bermejo-Barrera P, 2015. Variation of food mineral content during industrial
1528 and culinary processing. *Handbook of Mineral Elements in Food*:163-176. doi:
1529 10.1002/9781118654316.ch8

- 1530 Bazzano LA, 2008. Effects of soluble dietary fiber on low-density lipoprotein cholesterol and coronary
1531 heart disease risk. *Curr Atheroscler Rep*, 10:473-477. doi: 10.1007/s11883-008-0074-3
- 1532 Bechthold A, Boeing H, Schwedhelm C, Hoffmann G, Knüppel S, Iqbal K, De Henauw S, Michels N,
1533 Devleeschauwer B, Schlesinger S and Schwingshackl L, 2019. Food groups and risk of coronary
1534 heart disease, stroke and heart failure: A systematic review and dose-response meta-analysis of
1535 prospective studies. *Critical Reviews in Food Science and Nutrition*, 59:1071-1090. doi:
1536 10.1080/10408398.2017.1392288
- 1537 Bendsen NT, Christensen R, Bartels EM and Astrup A, 2011. Consumption of industrial and ruminant
1538 trans fatty acids and risk of coronary heart disease: a systematic review and meta-analysis of cohort
1539 studies. *European Journal of Clinical Nutrition*, 65:773-783. doi: 10.1038/ejcn.2011.34
- 1540 Bischoff-Ferrari HA, Dawson-Hughes B, Baron JA, Burckhardt P, Li R, Spiegelman D, Specker B, Orav
1541 JE, Wong JB, Staehelin HB, O'Reilly E, Kiel DP and Willett WC, 2007. Calcium intake and hip fracture
1542 risk in men and women: a meta-analysis of prospective cohort studies and randomized controlled
1543 trials. *American Journal of Clinical Nutrition*, 86:1780-1790. doi: 10.1093/ajcn/86.5.1780
- 1544 Boffetta P, Couto E, Wichmann J, Ferrari P, Trichopoulos D, Bueno-de-Mesquita HB, van Duijnhoven
1545 FJ, Büchner FL, Key T, Boeing H, Nöthlings U, Linseisen J, Gonzalez CA, Overvad K, Nielsen MR,
1546 Tjønneland A, Olsen A, Clavel-Chapelon F, Boutron-Ruault MC, Morois S, Lagiou P, Naska A, Benetou
1547 V, Kaaks R, Rohrmann S, Panico S, Sieri S, Vineis P, Palli D, van Gils CH, Peeters PH, Lund E, Brustad
1548 M, Engeset D, Huerta JM, Rodríguez L, Sánchez MJ, Dorronsoro M, Barricarte A, Hallmans G,
1549 Johansson I, Manjer J, Sonestedt E, Allen NE, Bingham S, Khaw KT, Slimani N, Jenab M, Mouw T,
1550 Norat T, Riboli E and Trichopoulou A, 2010. Fruit and vegetable intake and overall cancer risk in the
1551 European Prospective Investigation into Cancer and Nutrition (EPIC). *Journal of the National Cancer
1552 Institute*, 102:529-537. doi: 10.1093/jnci/djq072
- 1553 Borch D, Juul-Hindsgaul N, Veller M, Astrup A, Jaskolowski J and Raben A, 2016. Potatoes and risk of
1554 obesity, type 2 diabetes, and cardiovascular disease in apparently healthy adults: a systematic
1555 review of clinical intervention and observational studies. *American Journal of Clinical Nutrition*,
1556 104:489-498. doi: 10.3945/ajcn.116.132332
- 1557 Brannon PM and Taylor CL, 2017. Iron supplementation during pregnancy and infancy: Uncertainties
1558 and implications for research and policy. *Nutrients*, 9. doi: 10.3390/nu9121327
- 1559 Briggs MA, Petersen KS and Kris-Etherton PM, 2017. Saturated Fatty Acids and Cardiovascular Disease:
1560 Replacements for Saturated Fat to Reduce Cardiovascular Risk. *Healthcare (Basel)*, 5. doi:
1561 10.3390/healthcare5020029
- 1562 Capuano E, van der Veer G, Verheijen PJJ, Heenan SP, van de Laak LFJ, Koopmans HBM and van Ruth
1563 SM, 2013. Comparison of a sodium-based and a chloride-based approach for the determination of
1564 sodium chloride content of processed foods in the Netherlands. *Journal of Food Composition and
1565 Analysis*, 31:129-136. doi: 10.1016/j.jfca.2013.04.004
- 1566 Chen Z, Ahmed M, Ha V, Jefferson K, Malik V, Ribeiro PAB, Zuchinali P and Drouin-Chartier J-P, 2021.
1567 Dairy product consumption and cardiovascular health: a systematic review and meta-analysis of
1568 prospective cohort studies. *Advances in Nutrition*. doi: 10.1093/advances/nmab118
- 1569 Cummings J, 2001. The effect of dietary fiber on fecal weight and composition. In: Spiller G (ed.). *CRC
1570 Handbook of Dietary Fiber in Human Nutrition*, CRC Press, Boca Raton, Florida, USA. pp. 183–252.
- 1571 D-A-CH (Deutsche Gesellschaft für Ernährung, Österreichische Gesellschaft für Ernährung,
1572 Schweizerische Gesellschaft für Ernährung), 2015. Referenzwerte für die Nährstoffzufuhr. DGE,
1573 Bonn, Germany
- 1574 Davis C, Bryan J, Hodgson J and Murphy K, 2015. Definition of the Mediterranean Diet; a literature
1575 review. *Nutrients*, 7:9139-9153. doi: 10.3390/nu7115459
- 1576 de Souza RJ, Mente A, Maroleanu A, Cozma AI, Ha V, Kishibe T, Uleryk E, Budyłowski P, Schünemann
1577 H, Beyene J and Anand SS, 2015. Intake of saturated and trans unsaturated fatty acids and risk of
1578 all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis
1579 of observational studies. *BMJ*, 351:h3978. doi: 10.1136/bmj.h3978

- 1580 Devi A and Khatkar BS, 2018. Effects of fatty acids composition and microstructure properties of fats
1581 and oils on textural properties of dough and cookie quality. *Journal of Food Science and Technology*,
1582 55:321-330. doi: 10.1007/s13197-017-2942-8
- 1583 DH (Department of Health), 1991. Dietary reference values for food energy and nutrients for the United
1584 Kingdom. Report of the Panel on Dietary Reference Values of the Committee on Medical Aspects of
1585 Food Policy. HMSO, London, UK, 212 pp.
- 1586 Dold S, Zimmermann MB, Jukic T, Kusic Z, Jia Q, Sang Z, Quirino A, San Luis TOL, Fingerhut R, Kupka
1587 R, Timmer A, Garrett GS and Andersson M, 2018. Universal salt iodization provides sufficient dietary
1588 iodine to achieve adequate iodine nutrition during the first 1000 days: A cross-sectional multicenter
1589 study. *Journal of Nutrition*, 148:587-598. doi: 10.1093/jn/nxy015
- 1590 Drouin-Chartier JP, Brassard D, Tessier-Grenier M, Côté JA, Labonté M, Desroches S, Couture P and
1591 Lamarche B, 2016. Systematic review of the association between dairy product consumption and
1592 risk of cardiovascular-related clinical outcomes. *Advances in Nutrition*, 7:1026-1040. doi:
1593 10.3945/an.115.011403
- 1594 Du H, van der AD, Boshuizen HC, Forouhi NG, Wareham NJ, Halkjaer J, Tjønneland A, Overvad K,
1595 Jakobsen MU, Boeing H, Buijsse B, Masala G, Palli D, Sørensen TI, Saris WH and Feskens EJ, 2010.
1596 Dietary fiber and subsequent changes in body weight and waist circumference in European men and
1597 women. *American Journal of Clinical Nutrition*, 91:329-336. doi: 10.3945/ajcn.2009.28191
- 1598 EFSA (European Food Safety Authority), 2008. The setting of nutrient profiles for foods bearing nutrition
1599 and health claims pursuant to Article 4 of the Regulation (EC) No 1924/2006 - Scientific Opinion of
1600 the Panel on Dietetic Products, Nutrition and Allergies. *EFSA Journal* 2008; 6(2):644, 45 pp.
1601 doi:10.2903/j.efsa.2008.644
- 1602 EFSA, 2009. Scientific substantiation of a health claim related to Calcium plus Vitamin D3 chewing
1603 tablets and reduction of the risk of osteoporotic fractures by reducing bone loss pursuant to Article
1604 14 of Regulation (EC) No 1924/2006. *The EFSA Journal* (2009) 1180, 1-13,
1605 doi.org/10.2903/j.efsa.2009.1180
- 1606 EFSA (European Food Safety Authority), 2020. Draft framework for protocol development for EFSA's
1607 scientific assessments. EFSA supporting publication 2020:EN-1843. 46 pp.
1608 doi:10.2903/sp.efsa.2020.EN-1843
- 1609 EFSA NDA Panel, 2009. Scientific Opinion on the substantiation of health claims related to vitamin C
1610 and protection of DNA, proteins and lipids from oxidative damage (ID 129, 138, 143, 148),
1611 antioxidant function of lutein (ID 146), maintenance of vision (ID 141, 142), collagen formation (ID
1612 130, 131, 136, 137, 149), function of the nervous system (ID 133), function of the immune system
1613 (ID 134), function of the immune system during and after extreme physical exercise (ID 144), non-
1614 haem iron absorption (ID 132, 147), energy-yielding metabolism (ID 135), and relief in case of
1615 irritation in the upper respiratory tract (ID 1714, 1715) pursuant to Article 13(1) of Regulation (EC)
1616 No 1924/2006 on request from the European Commission *EFSA Journal* 2009; 7(9):1226, 28 pp.
1617 doi:10.2903/j.efsa.2009.1226
- 1618 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2010a. Scientific Opinion
1619 in relation to the authorisation procedure for health claims on calcium and vitamin D and the
1620 reduction of the risk of osteoporotic fractures by reducing bone loss pursuant to Article 14 of
1621 Regulation (EC) No 1924/2006. *EFSA Journal* 2010; 8(5):1609, 10 pp.
1622 doi:10.2903/j.efsa.2010.1609
- 1623 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition, and Allergies), 2010b. Scientific Opinion
1624 on Dietary Reference Values for carbohydrates and dietary fibre. *EFSA Journal* 2010; 8(3):1462, 77
1625 pp., doi:10.2903/j.efsa.2010.1462
- 1626 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition, and Allergies), 2010c. Scientific Opinion
1627 on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids,
1628 monounsaturated fatty acids, trans fatty acids, and cholesterol. *EFSA Journal* 2010; 8(3):1461.
1629 [107 pp.]. doi:10.2903/j.efsa.2010.1461

- 1630 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition, Allergies), 2010d. Scientific Opinion on
1631 establishing Food-Based Dietary Guidelines. EFSA Journal 2010; 8(3):1460. [42 pp.].
1632 doi:10.2903/j.efsa.2010.1460
- 1633 EFSA NDA Panel, 2010e. Scientific Opinion on the substantiation of health claims related to
1634 eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and
1635 maintenance of normal cardiac function (ID 504, 506, 516, 527, 538, 703, 1128, 1317, 1324, 1325),
1636 maintenance of normal blood glucose concentrations (ID 566), maintenance of normal blood
1637 pressure (ID 506, 516, 703, 1317, 1324), maintenance of normal blood HDL-cholesterol
1638 concentrations (ID 506), maintenance of normal (fasting) blood concentrations of triglycerides (ID
1639 506, 527, 538, 1317, 1324, 1325), maintenance of normal blood LDL-cholesterol concentrations (ID
1640 527, 538, 1317, 1325, 4689), protection of the skin from photo-oxidative (UV-induced) damage (ID
1641 530), improved absorption of EPA and DHA (ID 522, 523), contribution to the normal function of
1642 the immune system by decreasing the levels of eicosanoids, arachidonic acid-derived mediators and
1643 pro-inflammatory cytokines (ID 520, 2914), and "immunomodulating agent" (4690) pursuant to
1644 Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2010;8(10):1796, 32 pp.
1645 doi:10.2903/j.efsa.2010.1796
- 1646 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2010f. Scientific Opinion on
1647 the substantiation of health claims related to stearic acid and maintenance of normal blood
1648 cholesterol concentrations (ID 716, 1657) pursuant to Article 13(1) of Regulation (EC) No
1649 1924/2006. EFSA Journal 2010; 8(2):1476, 14 pp. doi:10.2903/j.efsa.2010.1476
- 1650 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011a. Scientific Opinion
1651 on the substantiation of a health claim related to vitamin D and risk of falling pursuant to Article 14
1652 of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(9):2382, 18 pp.
1653 doi:10.2903/j.efsa.2011.2382
- 1654 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011b. Scientific Opinion
1655 on the substantiation of health claims related to foods with reduced amounts of saturated fatty acids
1656 (SFAs) and maintenance of normal blood LDL-cholesterol concentrations (ID 620, 671, 4332)
1657 pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(4):2062 [14 pp.].
1658 doi:10.2903/j.efsa.2011.2062
- 1659 EFSA NDA Panel (FSA Panel on Dietetic Products, Nutrition and Allergies), 2011c. Scientific Opinion on
1660 the substantiation of health claims related to polyphenols in olive and protection of LDL particles
1661 from oxidative damage (ID 1333, 1638, 1639, 1696, 2865), maintenance of normal blood HDL-
1662 cholesterol concentrations (ID 1639), maintenance of normal blood pressure (ID 3781), "anti-
1663 inflammatory properties" (ID 1882), "contributes to the upper respiratory tract health" (ID 3468),
1664 "can help to maintain a normal function of gastrointestinal tract" (3779), and "contributes to body
1665 defences against external agents" (ID 3467) pursuant to Article 13(1) of Regulation (EC) No 1924/2006.
1666 EFSA Journal 2011;9(4):2033, 25 pp. doi:10.2903/j.efsa.2011.2033
- 1667 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2011d. Scientific Opinion
1668 on the substantiation of health claims related to the replacement of mixtures of saturated fatty acids
1669 (SFAs) as present in foods or diets with mixtures of monounsaturated fatty acids (MUFAs) and/or
1670 mixtures of polyunsaturated fatty acids (PUFAs), and maintenance of normal blood LDL-cholesterol
1671 concentrations (ID 621, 1190, 1203, 2906, 2910, 3065) pursuant to Article 13(1) of Regulation (EC)
1672 No 1924/2006. EFSA Journal 2011;9(4):2069. [18 pp.]. doi:10.2903/j.efsa.2011.2069
- 1673 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2012a. Scientific Opinion
1674 on Dietary Reference Values for protein. EFSA Journal 2012;10(2):2557, 66 pp.
1675 doi:10.2903/j.efsa.2012.2557
- 1676 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2012b. Scientific Opinion
1677 related to the Tolerable Upper Intake Level of eicosapentaenoic acid (EPA), docosahexaenoic acid
1678 (DHA) and docosapentaenoic acid (DPA). EFSA Journal 2012;10(7):2815, 48 pp.
1679 doi:10.2903/j.efsa.2012.2815
- 1680 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2013. Scientific Opinion on
1681 Dietary Reference Values for energy. EFSA Journal 2013;11(1):3005, 112 pp.
1682 doi:10.2903/j.efsa.2013.3005

- 1683 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2014a. Scientific Opinion
1684 on Dietary Reference Values for folate. EFSA Journal 2014;12(11):3893, 59 pp.
1685 doi:10.2903/j.efsa.2014.3893
- 1686 EFSA NDA Panel (EFSA Panel on Panel on Dietetic Products Nutrition and Allergies), 2014b. Scientific
1687 Opinion on Dietary Reference Values for iodine. EFSA Journal 2014;12(5):3660, 57 pp.
1688 doi:10.2903/j.efsa.2014.3660
- 1689 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2014c. Scientific Opinion
1690 on health benefits of seafood (fish and shellfish) consumption in relation to health risks associated
1691 with exposure to methylmercury. EFSA Journal 2014;12(7):3761, 80 pp.
1692 doi:10.2903/j.efsa.2014.3761
- 1693 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2015a. Scientific Opinion
1694 on Dietary Reference Values for calcium. EFSA Journal 2015;13(5):4101, 82 pp.
1695 doi:10.2903/j.efsa.2015.4101
- 1696 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2015b. Scientific Opinion
1697 on Dietary Reference Values for iron. EFSA Journal 2015;13(10):4254, 115 pp.
1698 doi:10.2903/j.efsa.2015.4254
- 1699 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2016a. Scientific opinion on
1700 Dietary Reference Values for potassium. EFSA Journal 2016;14(10):4592, 56 pp.
1701 doi:10.2903/j.efsa.2016.4592
- 1702 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2016b. Scientific opinion on
1703 Dietary Reference Values for vitamin D. EFSA Journal 2016;14(10):4547, 145 pp.
1704 doi:10.2903/j.efsa.2016.4547
- 1705 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2017. Scientific Opinion on
1706 the safety and suitability for use by infants of follow-on formulae with a protein content of at least
1707 1.6 g/100 kcal. EFSA Journal 2017;15(5):4781, 29 pp. doi: 10.2903/j.efsa.2017.4781
- 1708 EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2018. Guidance for the
1709 scientific requirements for health claims related to antioxidants, oxidative damage and
1710 cardiovascular health (Revision 1). EFSA Journal 2018;16(1):5136, 21 pp. doi:
1711 10.2903/j.efsa.2018.5136
- 1712 EFSA NDA Panel, 2019a. Scientific Opinion on the appropriate age range for introduction of
1713 complementary feeding into an infant's diet. EFSA Journal 2019;17(9):5780, 241 pp.
1714 doi.org/10.2903/j.efsa.2019.5780
- 1715 EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), 2019b. Scientific Opinion
1716 on the Dietary Reference Values for sodium. EFSA Journal 2019;17(9):5778, 191 pp. doi:
1717 10.2903/j.efsa.2019.5778
- 1718 EFSA NDA Panel (EFSA Panel on Nutrition, Novel Foods and Food Allergens), 2021. Draft scientific
1719 opinion on the Tolerable Upper Intake Level for dietary sugars released for public consultation. 354
1720 pp
- 1721 Eilander A, Harika RK and Zock PL, 2015. Intake and sources of dietary fatty acids in Europe: Are
1722 current population intakes of fats aligned with dietary recommendations? European Journal of Lipid
1723 Science and Technology, 117:1370-1377. doi: 10.1002/ejlt.201400513
- 1724 Elia M and Cummings JH, 2007. Physiological aspects of energy metabolism and gastrointestinal effects
1725 of carbohydrates. European Journal of Clinical Nutrition, 61:S40-S74. doi: 10.1038/sj.ejcn.1602938
- 1726 Ellegård L and Andersson H, 2007. Oat bran rapidly increases bile acid excretion and bile acid synthesis:
1727 an ileostomy study. European Journal of Clinical Nutrition, 61:938-945. doi:
1728 10.1038/sj.ejcn.1602607
- 1729 European Commission, 2012. Survey on Members States' implementation of the EU salt reduction
1730 framework. 26 pp. Available online: [https://ec.europa.eu/health/sites/health/files/
1731 _physical_activity/docs/salt_report1_en.pdf](https://ec.europa.eu/health/sites/health/files/_physical_activity/docs/salt_report1_en.pdf)

- 1732 Eyles H, Webster J, Jebb S, Capelin C, Neal B and Ni Mhurchu C, 2013. Impact of the UK voluntary
1733 sodium reduction targets on the sodium content of processed foods from 2006 to 2011: analysis of
1734 household consumer panel data. *Preventive Medicine*, 57:555-560. doi:
1735 10.1016/j.ypmed.2013.07.024
- 1736 Fan M, Li Y, Wang C, Mao Z, Zhou W, Zhang L, Yang X, Cui S and Li L, 2019. Dietary protein consumption
1737 and the risk of type 2 diabetes: A dose-response meta-analysis of prospective studies. *Nutrients*,
1738 11. doi: 10.3390/nu11112783
- 1739 Fewtrell M, Bronsky J, Campoy C, Domellof M, Embleton N, Fidler Mis N, Hojsak I, Hulst JM, Indrio F,
1740 Lapillonne A and Molgaard C, 2017. Complementary feeding: A position paper by the European
1741 Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Committee on
1742 Nutrition. *Journal of Pediatric Gastroenterology and Nutrition*, 64:119-132. doi:
1743 10.1097/MPG.0000000000001454
- 1744 Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju Sh N, Wormser D, Gao P, Kaptoge
1745 S, Berrington de Gonzalez A, Cairns BJ, Huxley R, Jackson Ch L, Joshy G, Lewington S, Manson JE,
1746 Murphy N, Patel AV, Samet JM, Woodward M, Zheng W, Zhou M, Bansal N, Barricarte A, Carter B,
1747 Cerhan JR, Smith GD, Fang X, Franco OH, Green J, Halsey J, Hildebrand JS, Jung KJ, Korda RJ,
1748 McLerran DF, Moore SC, O'Keefe LM, Paige E, Ramond A, Reeves GK, Rolland B, Sacerdote C, Sattar
1749 N, Sofianopoulou E, Stevens J, Thun M, Ueshima H, Yang L, Yun YD, Willeit P, Banks E, Beral V,
1750 Chen Z, Gapstur SM, Gunter MJ, Hartge P, Jee SH, Lam TH, Peto R, Potter JD, Willett WC, Thompson
1751 SG, Danesh J and Hu FB, 2016. Body-mass index and all-cause mortality: individual-participant-data
1752 meta-analysis of 239 prospective studies in four continents. *Lancet*, 388:776-786. doi:
1753 10.1016/S0140-6736(16)30175-1
- 1754 Guo F, Zhang Q, Jiang H, He Y, Li M, Ran J, Lin J, Tian L and Ma L, 2021. Dietary potato intake and
1755 risks of type 2 diabetes and gestational diabetes mellitus. *Clinical Nutrition*, 40:3754-3764. doi:
1756 <https://doi.org/10.1016/j.clnu.2021.04.039>
- 1757 Guo J, Astrup A, Lovegrove JA, Gijsbers L, Givens DI and Soedamah-Muthu SS, 2017. Milk and dairy
1758 consumption and risk of cardiovascular diseases and all-cause mortality: dose-response meta-
1759 analysis of prospective cohort studies. *European Journal of Epidemiology*, 32:269-287. doi:
1760 10.1007/s10654-017-0243-1
- 1761 Hall KD, Sacks G, Chandramohan D, Chow CC, Wang YC, Gortmaker SL and Swinburn BA, 2011.
1762 Quantification of the effect of energy imbalance on bodyweight. *Lancet*, 378:826-837. doi:
1763 10.1016/S0140-6736(11)60812-X
- 1764 Health Council of the Netherlands, 2018. Dietary Reference Values for vitamins and minerals for adults.
1765 No. 2018/19e, 34 pp.
- 1766 IoM (Institute of Medicine), 1998. Dietary Reference Intakes for thiamin, riboflavin, niacin, vitamin B6,
1767 folate, vitamin B12, pantothenic acid, biotin, and choline. Food and Nutrition Board. National
1768 Academy Press, Washington, DC, USA, 591 pp.
- 1769 IoM (Institute of Medicine), 2011. Dietary Reference Intakes for calcium and vitamin D. National
1770 Academies Press, Washington, D.C., USA, 1133 pp.
- 1771 Ittermann T, Albrecht D, Arohonka P, Bilek R, de Castro JJ, Dahl L, Filipsson Nystrom H, Gaberscek S,
1772 Garcia-Fuentes E, Gheorghiu ML, Hubalewska-Dydejczyk A, Hunziker S, Jukic T, Karanfilski B,
1773 Koskinen S, Kusic Z, Majstorov V, Makris KC, Markou KB, Meisinger C, Milevska Kostova N, Mullen
1774 KR, Nagy EV, Pirags V, Rojo-Martinez G, Samardzic M, Saranac L, Strele I, Thamm M, Top I,
1775 Trofimiuk-Müldner M, Ünal B, Koskinen S, Vila L, Vitti P, Winter B, Woodside JV, Zaletel K, Zamrazil
1776 V, Zimmermann M, Erlund I and Völzke H, 2020. Standardized map of iodine status in Europe.
1777 *Thyroid*, 30:1346-1354. doi: 10.1089/thy.2019.0353
- 1778 Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM,
1779 Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe
1780 BM and Yanovski SZ, 2014. 2013 AHA/ACC/TOS Guideline for the management of overweight and
1781 obesity in adults. *Circulation*, 129:S102-S138. doi: doi:10.1161/01.cir.0000437739.71477.ee

- 1782 Jepsen S, Blanco J, Buchalla W, Carvalho JC, Dietrich T, Dörfer C, Eaton KA, Figuero E, Frencken JE,
1783 Graziani F, Higham SM, Kocher T, Maltz M, Ortiz-Vigon A, Schmoeckel J, Sculean A, Tenuta LM, van
1784 der Veen MH and Machiulskiene V, 2017. Prevention and control of dental caries and periodontal
1785 diseases at individual and population level: consensus report of group 3 of joint EFP/ORCA workshop
1786 on the boundaries between caries and periodontal diseases. *Journal of Clinical Periodontology*, 44
1787 Suppl 18:S85-s93. doi: 10.1111/jcpe.12687
- 1788 Kang ZQ, Yang Y and Xiao B, 2020. Dietary saturated fat intake and risk of stroke: Systematic review
1789 and dose-response meta-analysis of prospective cohort studies. *Nutrition, Metabolism, and*
1790 *Cardiovascular Diseases*, 30:179-189. doi: 10.1016/j.numecd.2019.09.028
- 1791 Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Willers C and
1792 Borgstrom F, 2021. SCOPE 2021: a new scorecard for osteoporosis in Europe. *Archives of*
1793 *Osteoporosis*, 16:82. doi: 10.1007/s11657-020-00871-9
- 1794 Kloss L, Meyer JD, Graeve L and Vetter W, 2015. Sodium intake and its reduction by food reformulation
1795 in the European Union — A review. *NFS Journal*, 1:9-19. doi: 10.1016/j.nfs.2015.03.001
- 1796 Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton
1797 C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D,
1798 Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ and the ESC Scientific
1799 Document Group, 2019. 2019 ESC Guidelines for the diagnosis and management of chronic coronary
1800 syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of
1801 the European Society of Cardiology (ESC). *European Heart Journal*, 41:407-477. doi:
1802 10.1093/eurheartj/ehz425
- 1803 Koh-Banerjee P, Chu NF, Spiegelman D, Rosner B, Colditz G, Willett W and Rimm E, 2003. Prospective
1804 study of the association of changes in dietary intake, physical activity, alcohol consumption, and
1805 smoking with 9-y gain in waist circumference among 16 587 US men. *American Journal of Clinical*
1806 *Nutrition*, 78:719-727. doi: 10.1093/ajcn/78.4.719
- 1807 Labonté M, Poon T, Gladanac B, Ahmed M, Franco-Arellano B, Rayner M and L'Abbé MR, 2018. Nutrient
1808 profile models with applications in government-led nutrition policies aimed at health promotion and
1809 noncommunicable disease prevention: A systematic review. *Advances in Nutrition*, 9:741-788. doi:
1810 10.1093/advances/nmy045
- 1811 Ma C, Avenell A, Bolland M, Hudson J, Stewart F, Robertson C, Sharma P, Fraser C and MacLennan G,
1812 2017. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular
1813 disease, and cancer: systematic review and meta-analysis. *BMJ*, 359:j4849. doi: 10.1136/bmj.j4849
- 1814 Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG,
1815 Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi
1816 G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglul, Wiklund O and Group ESCSD, 2020. 2019
1817 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce
1818 cardiovascular risk. *European Heart Journal*, 41:111-188. doi: 10.1093/eurheartj/ehz455
- 1819 Mayhew AJ, de Souza RJ, Meyre D, Anand SS and Mente A, 2016. A systematic review and meta-
1820 analysis of nut consumption and incident risk of CVD and all-cause mortality. *British Journal of*
1821 *Nutrition*, 115:212-225. doi: 10.1017/S0007114515004316
- 1822 McRae MP, 2017. Dietary fiber Is beneficial for the prevention of cardiovascular disease: An umbrella
1823 review of meta-analyses. *Journal of Chiropractic Medicine*, 16:289-299. doi:
1824 10.1016/j.jcm.2017.05.005
- 1825 Micha R, Khatibzadeh S, Shi P, Fahimi S, Lim S, Andrews KG, Engell RE, Powles J, Ezzati M, Mozaffarian
1826 D and the Global Burden of Diseases Nutrition and Chronic Diseases Expert Group, 2014. Global,
1827 regional, and national consumption levels of dietary fats and oils in 1990 and 2010: a systematic
1828 analysis including 266 country-specific nutrition surveys. *BMJ*, 348:g2272. doi: 10.1136/bmj.g2272
- 1829 Micha R, Wallace SK and Mozaffarian D, 2010. Red and processed meat consumption and risk of incident
1830 coronary heart disease, stroke, and diabetes mellitus: a systematic review and meta-analysis.
1831 *Circulation*, 121:2271-2283. doi: 10.1161/circulationaha.109.924977

- 1832 Milman NT, 2019. Dietary iron intake in women of reproductive age in Europe: A review of 49 studies
1833 from 29 countries in the period 1993–2015. *Journal of Nutrition and Metabolism*, 2019:7631306.
1834 doi: 10.1155/2019/7631306
- 1835 Milman NT, 2020a. Dietary iron intake in pregnant women in Europe: A review of 24 studies from 14
1836 countries in the period 1991–2014. *Journal of Nutrition and Metabolism*, 2020:7102190. doi:
1837 10.1155/2020/7102190
- 1838 Milman NT, 2020b. Dietary iron intakes in men in Europe are distinctly above the recommendations: A
1839 review of 39 national studies from 20 countries in the period 1995 - 2016. *Gastroenterology*
1840 *Research*, 13:233-245. doi: 10.14740/gr1344
- 1841 Mithril C, Dragsted LO, Meyer C, Blauert E, Holt MK and Astrup A, 2012. Guidelines for the New Nordic
1842 Diet. *Public Health Nutrition*, 15:1941-1947. doi: 10.1017/S136898001100351X
- 1843 Mithril C, Dragsted LO, Meyer C, Tetens I, Biloft-Jensen A and Astrup A, 2013. Dietary composition
1844 and nutrient content of the New Nordic Diet. *Public Health Nutrition*, 16:777-785. doi:
1845 10.1017/s1368980012004521
- 1846 Mongraw-Chaffin ML, Peters SAE, Huxley RR and Woodward M, 2015. The sex-specific association
1847 between BMI and coronary heart disease: a systematic review and meta-analysis of 95 cohorts with
1848 1.2 million participants. *The Lancet Diabetes & Endocrinology*, 3:437-449. doi: 10.1016/S2213-
1849 8587(15)00086-8
- 1850 Mouratidou T, Livanou A, Martín Saborido C, Wollgast J and Caldeira S, 2014. Trans fatty acids in
1851 Europe: where do we stand? JRC Science and Policy Reports, 68 pp.
- 1852 Mozaffarian D, 2016. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: A
1853 comprehensive review. *Circulation*, 133:187-225. doi: 10.1161/circulationaha.115.018585
- 1854 Mozaffarian D, Dashti HS, Wojczynski MK, Chu AY, Nettleton JA, Männistö S, Kristiansson K, Reedik M,
1855 Lahti J, Houston DK, Cornelis MC, van Rooij FJA, Dimitriou M, Kanoni S, Mikkilä V, Steffen LM, de
1856 Oliveira Otto MC, Qi L, Psaty B, Djousse L, Rotter JI, Harald K, Perola M, Rissanen H, Jula A, Krista
1857 F, Mihailov E, Feitosa MF, Ngwa JS, Xue L, Jacques PF, Perälä MM, Palotie A, Liu Y, Nalls NA, Ferrucci
1858 L, Hernandez D, Manichaikul A, Tsai MY, Kieft-de Jong JC, Hofman A, Uitterlinden AG, Rallidis L,
1859 Ridker PM, Rose LM, Buring JE, Lehtimäki T, Kähönen M, Viikari J, Lemaitre R, Salomaa V, Knekt P,
1860 Metspalu A, Borecki IB, Cupples LA, Eriksson JG, Kritchevsky SB, Bandinelli S, Siscovick D, Franco
1861 OH, Deloukas P, Dedoussis G, Chasman DI, Raitakari O and Tanaka T, 2017. Genome-wide
1862 association meta-analysis of fish and EPA+DHA consumption in 17 US and European cohorts. *PLoS*
1863 *ONE*, 12:e0186456. doi: 10.1371/journal.pone.0186456
- 1864 Mozaffarian D, Micha R and Wallace S, 2010. Effects on coronary heart disease of increasing
1865 polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized
1866 controlled trials. *PLoS Medicine*, 7:e1000252. doi: 10.1371/journal.pmed.1000252
- 1867 Mozaffarian D and Rimm EB, 2006. Fish intake, contaminants, and human health: Evaluating the risks
1868 and the benefits. *JAMA*, 296:1885-1899. doi: 10.1001/jama.296.15.1885
- 1869 Mozaffarian D and Wu JH, 2011. Omega-3 fatty acids and cardiovascular disease: effects on risk factors,
1870 molecular pathways, and clinical events. *Journal of the American College of Cardiology*, 58:2047-
1871 2067. doi: 10.1016/j.jacc.2011.06.063
- 1872 NASEM (National Academies of Sciences, Engineering, and Medicine), 2019. Dietary Reference Intakes
1873 for sodium and potassium. The National Academies Press, Washington, DC, USA. 498 pp. Available
1874 online: <https://www.nap.edu/read/25353/chapter/1>
- 1875 Neuenschwander M, Ballon A, Weber KS, Norat T, Aune D, Schwingshackl L and Schlesinger S, 2019.
1876 Role of diet in type 2 diabetes incidence: umbrella review of meta-analyses of prospective
1877 observational studies. *BMJ*, 366:l2368. doi: 10.1136/bmj.l2368
- 1878 NHMRC (National Health and Medical Research Council), 2017. Nutrient Reference Values for Australia
1879 and New Zealand including Recommended Dietary Intake. 320 pp.

- 1880 Ni Mhurchu C, Capelin C, Dunford EK, Webster JL, Neal BC and Jebb SA, 2011. Sodium content of
1881 processed foods in the United Kingdom: analysis of 44,000 foods purchased by 21,000 households.
1882 *American Journal of Clinical Nutrition*, 93:594-600. doi: 10.3945/ajcn.110.004481
- 1883 NICE (National Institute for Health and Care Excellence), 2014. Vitamin D: supplement use in specific
1884 population groups. Public health guideline PH56, 55 pp.
- 1885 NICE (National Institute for Health and Care Excellence), 2015. Preventing excess weight gain. NICE
1886 Guideline NG7, 55 pp.
- 1887 Nordic Council of Ministers, 2014. Nordic Nutrition Recommendations 2012. Integrating nutrition and
1888 physical activity. 5th edition. 627 pp.
- 1889 Papier K, Knuppel A, Syam N, Jebb SA and Key TJ, 2021. Meat consumption and risk of ischemic heart
1890 disease: A systematic review and meta-analysis. *Critical Reviews in Food Science and Nutrition*:1-
1891 12. doi: 10.1080/10408398.2021.1949575
- 1892 Portalatin M and Winstead N, 2012. Medical management of constipation. *Clinics in Colon and Rectal
1893 Surgery*, 25:12-19. doi: 10.1055/s-0032-1301754
- 1894 Puska P and Ståhl T, 2010. Health in all policies-the Finnish initiative: background, principles, and
1895 current issues. *Annual Review of Public Health*, 31:315-328. doi:
1896 10.1146/annurev.publhealth.012809.103658
- 1897 Quan W, Jiao Y, Xue C, Li Y, Wang Z, Zeng M, Qin F, He Z and Chen J, 2020. Processed potatoes intake
1898 and risk of type 2 diabetes: a systematic review and meta-analysis of nine prospective cohort
1899 studies. *Critical Reviews in Food Science and Nutrition*:1-9. doi: 10.1080/10408398.2020.1843395
- 1900 Rand WM, Pellett PL and Young VR, 2003. Meta-analysis of nitrogen balance studies for estimating
1901 protein requirements in healthy adults. *American Journal of Clinical Nutrition*, 77:109-127. doi:
1902 10.1093/ajcn/77.1.109
- 1903 Rimm EB, Appel LJ, Chiuve SE, Djoussé L, Engler MB, Kris-Etherton PM, Mozaffarian D, Siscovick DS,
1904 Lichtenstein AH, the American Heart Association Nutrition Committee of the Council on Lifestyle and
1905 Cardiometabolic Health, the Council on Epidemiology and Prevention, the Council on Cardiovascular
1906 Disease in the Young, the Council on Cardiovascular and Stroke Nursing and the Council on Clinical
1907 Cardiology, 2018. Seafood long-chain n-3 polyunsaturated fatty acids and cardiovascular disease: A
1908 science advisory from the American Heart Association. *Circulation*, 138:e35-e47. doi:
1909 10.1161/CIR.0000000000000574
- 1910 Roe MA, Bell S, Oseredczuk M, Christensen T, Westenbrink S, Pakkala H, Presser K and Finglas PM,
1911 2013. Updated food composition database for nutrient intake. EFSA supporting publication 2013:EN-
1912 355, 21 pp.
- 1913 Rong Y, Chen L, Zhu T, Song Y, Yu M, Shan Z, Sands A, Hu FB and Liu L, 2013. Egg consumption and
1914 risk of coronary heart disease and stroke: dose-response meta-analysis of prospective cohort
1915 studies. *BMJ*, 346:e8539. doi: 10.1136/bmj.e8539
- 1916 Rosato V, Temple NJ, La Vecchia C, Castellan G, Tavani A and Guercio V, 2019. Mediterranean diet and
1917 cardiovascular disease: a systematic review and meta-analysis of observational studies. *European
1918 Journal of Nutrition*, 58:173-191. doi: 10.1007/s00394-017-1582-0
- 1919 Rusińska A, Płudowski P, Walczak M, Borszewska-Kornacka MK, Bossowski A, Chlebna-Sokół D, Czech-
1920 Kowalska J, Dobrzańska A, Franek E, Helwich E, Jackowska T, Kalina MA, Konstantynowicz J, Książek
1921 J, Lewiński A, Łukaszkiwicz J, Marcinowska-Suchowierska E, Mazur A, Michałus I, Peregud-
1922 Pogorzelski J, Romanowska H, Ruchała M, Socha P, Szalecki M, Wielgoś M, Zwolińska D and Zygmunt
1923 A, 2018. Vitamin D supplementation guidelines for general population and groups at risk of vitamin
1924 D deficiency in Poland-Recommendations of the Polish Society of Pediatric Endocrinology and
1925 Diabetes and the Expert Panel with participation of national specialist consultants and
1926 representatives of scientific societies-2018 update. *Frontiers in Endocrinology*, 9:246. doi:
1927 10.3389/fendo.2018.00246
- 1928 SACN (Scientific Advisory Committee on Nutrition), 2017. Update on folic acid. 82 pp.

- 1929 Santos M, Rito AI, Matias FN, Assunção R, Castanheira I and Loureiro I, 2021. Nutrient profile models
1930 a useful tool to facilitate healthier food choices: A comprehensive review. *Trends in Food Science &*
1931 *Technology*, 110:120-131. doi: 10.1016/j.tifs.2021.01.082
- 1932 Schwingshackl L, Hoffmann G, Lampousi AM, Knüppel S, Iqbal K, Schwedhelm C, Bechthold A,
1933 Schlesinger S and Boeing H, 2017. Food groups and risk of type 2 diabetes mellitus: a systematic
1934 review and meta-analysis of prospective studies. *European Journal of Epidemiology*, 32:363-375.
1935 doi: 10.1007/s10654-017-0246-y
- 1936 Schwingshackl L, Zähringer J, Beyerbach J, Werner SW, Hesecker H, Koletzko B and Meerpohl JJ, 2021.
1937 Total Dietary Fat Intake, Fat Quality, and Health Outcomes: A Scoping Review of Systematic Reviews
1938 of Prospective Studies. *Annals of Nutrition and Metabolism*, 77:4-15. doi: 10.1159/000515058
- 1939 Siri-Tarino PW, Sun Q, Hu FB and Krauss RM, 2010. Meta-analysis of prospective cohort studies
1940 evaluating the association of saturated fat with cardiovascular disease. *American Journal of Clinical*
1941 *Nutrition*, 91:535-546. doi: 10.3945/ajcn.2009.27725
- 1942 Spiro A and Buttriss JL, 2014. Vitamin D: An overview of vitamin D status and intake in Europe. *Nutrition*
1943 *Bulletin*, 39:322-350. doi: 10.1111/nbu.12108
- 1944 Stephen AM, Champ MM, Cloran SJ, Fleith M, van Lieshout L, Mejbourn H and Burley VJ, 2017. Dietary
1945 fibre in Europe: current state of knowledge on definitions, sources, recommendations, intakes and
1946 relationships to health. *Nutrition Research Reviews*, 30:149-190. doi: 10.1017/S095442241700004X
- 1947 Storcksdieck genannt Bonsmann S, Marandola G, Ciriolo E, Bavel Rv and Wollgast J (Joint Research
1948 Centre), 2020. Front-of-pack nutrition labelling schemes: a comprehensive review. EUR 29811 EN,
1949 Luxembourg, Publications Office of the European Union, 2020, ISBN 978-92-76-08970-4,
1950 doi:10.2760/180167, JRC113586, 202 pp.
- 1951 Thanapluetiwong S, Chewcharat A, Takkavatakarn K, Praditpornsilpa K, Eiam-Ong S and
1952 Susantitaphong P, 2020. Vitamin D supplement on prevention of fall and fracture: A meta-analysis
1953 of randomized controlled trials. *Medicine*, 99:e21506. doi: 10.1097/md.00000000000021506
- 1954 Threapleton DE, Greenwood DC, Evans CE, Cleghorn CL, Nykjaer C, Woodhead C, Cade JE, Gale CP
1955 and Burley VJ, 2013. Dietary fibre intake and risk of cardiovascular disease: systematic review and
1956 meta-analysis. *BMJ*, 347:f6879. doi: 10.1136/bmj.f6879
- 1957 Tian S, Xu Q, Jiang R, Han T, Sun C and Na L, 2017. Dietary protein consumption and the risk of type
1958 2 diabetes: A systematic review and meta-analysis of cohort studies. *Nutrients*, 9. doi:
1959 10.3390/nu9090982
- 1960 USDA (United States Department of Agriculture), 2020. Dietary Guidelines for Americans 2020-2025.
1961 164 pp.
- 1962 van der Reijden OL, Zimmermann MB and Galetti V, 2017. Iodine in dairy milk: Sources, concentrations
1963 and importance to human health. *Best Practice & Research Clinical Endocrinology & Metabolism*,
1964 31:385-395. doi: 10.1016/j.beem.2017.10.004
- 1965 Vinceti M, Filippini T, Crippa A, de Sesmaisons A, Wise LA and Orsini N, 2016. Meta-analysis of
1966 potassium intake and the risk of stroke. *Journal of the American Heart Association*, 5. doi:
1967 10.1161/JAHA.116.004210
- 1968 Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida J-M,
1969 Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH,
1970 Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L,
1971 Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B and the E. S. C. Scientific
1972 Document Group, 2021. 2021 ESC Guidelines on cardiovascular disease prevention in clinical
1973 practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with
1974 representatives of the European Society of Cardiology and 12 medical societies; with the special
1975 contribution of the European Association of Preventive Cardiology (EAPC). *European Heart Journal*.
1976 doi: 10.1093/eurheartj/ehab484

- 1977 Wang DD, Li Y, Bhupathiraju SN, Rosner BA, Sun Q, Giovannucci EL, Rimm EB, Manson JE, Willett WC,
1978 Stampfer MJ and Hu FB, 2021. Fruit and vegetable intake and mortality: Results from 2 prospective
1979 cohort studies of US men and women and a meta-analysis of 26 cohort studies. *Circulation*,
1980 143:1642-1654. doi: 10.1161/circulationaha.120.048996
- 1981 Wang X, Lin X, Ouyang YY, Liu J, Zhao G, Pan A and Hu FB, 2016. Red and processed meat consumption
1982 and mortality: dose-response meta-analysis of prospective cohort studies. *Public Health Nutrition*,
1983 19:893-905. doi: 10.1017/s1368980015002062
- 1984 Wang X, Ouyang Y, Liu J, Zhu M, Zhao G, Bao W and Hu FB, 2014. Fruit and vegetable consumption
1985 and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-
1986 response meta-analysis of prospective cohort studies. *BMJ*, 349:g4490. doi: 10.1136/bmj.g4490
- 1987 Wang Y, Harding SV, Thandapilly SJ, Tosh SM, Jones PJH and Ames NP, 2017. Barley β -glucan reduces
1988 blood cholesterol levels via interrupting bile acid metabolism. *British Journal of Nutrition*, 118:822-
1989 829. doi: 10.1017/s0007114517002835
- 1990 WCRF/AICR (World Cancer Research Fund/American Institute for Cancer Research), 2018. Diet,
1991 nutrition and physical activity and cancer: a global perspective. 116 pp. Available at:
1992 <https://www.wcrf.org/diet-and-cancer/>
- 1993 Webster JL, Dunford EK and Neal BC, 2010. A systematic survey of the sodium contents of processed
1994 foods. *American Journal of Clinical Nutrition*, 91:413-420. doi: 10.3945/ajcn.2009.28688
- 1995 WHO (World Health Organization), 2003. Diet, nutrition and the prevention of chronic diseases: report
1996 of a joint WHO/FAO expert consultation. WHO technical report series; 916, 160 pp.
- 1997 WHO (World Health Organization), 2004. Iodine status worldwide - WHO global database on iodine
1998 deficiency. 58 pp.
- 1999 WHO (World Health Organization), 2012. Guideline: Potassium intake for adults and children. 52 pp.
- 2000 WHO (World Health Organization), 2015a. Guideline: sugars intake for adults and children. 59 pp.
- 2001 WHO (World Health Organization), 2015b. WHO Regional Office for Europe nutrient profile model. 11
2002 pp.
- 2003 WHO (World Health Organization), 2019. Guiding principles and framework manual for front-of-pack
2004 labelling for promoting healthy diet. 46 pp
- 2005 WHO/FAO (World Health Organization/Food and Agriculture Organization of the United Nations), 2004.
2006 Vitamin and mineral requirements in human nutrition: report of a Joint FAO/WHO Expert
2007 Consultation, Bangkok, Thailand, 21-30 September 1998. 341 pp.
- 2008 Willett W, Rockstrom J, Loken B, Springmann M, Lang T, Vermeulen S, Garnett T, Tilman D, DeClerck
2009 F, Wood A, Jonell M, Clark M, Gordon LJ, Fanzo J, Hawkes C, Zurayk R, Rivera JA, De Vries W,
2010 Majele Sibanda L, Afshin A, Chaudhary A, Herrero M, Agustina R, Branca F, Lartey A, Fan S, Crona
2011 B, Fox E, Bignet V, Troell M, Lindahl T, Singh S, Cornell SE, Srinath Reddy K, Narain S, Nishtar S
2012 and Murray CJL, 2019. Food in the Anthropocene: the EAT-Lancet Commission on healthy diets from
2013 sustainable food systems. *Lancet*, 393:447-492. doi: 10.1016/S0140-6736(18)31788-4
- 2014 Willett WC, Howe GR and Kushi LH, 1997. Adjustment for total energy intake in epidemiologic studies.
2015 *American Journal of Clinical Nutrition*, 65:1220S-1228S; discussion 1229S-1231S. doi:
2016 10.1093/ajcn/65.4.1220S
- 2017 Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone
2018 G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz
2019 R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis
2020 C, Aboyans V, Desormais I and the E. S. C. Scientific Document Group, 2018. 2018 ESC/ESH
2021 Guidelines for the management of arterial hypertension. *European Heart Journal*, 39:3021-3104.
2022 doi: 10.1093/eurheartj/ehy339
- 2023 Wolever TM, Tosh SM, Gibbs AL, Brand-Miller J, Duncan AM, Hart V, Lamarche B, Thomson BA, Duss
2024 R and Wood PJ, 2010. Physicochemical properties of oat β -glucan influence its ability to reduce
2025 serum LDL cholesterol in humans: a randomized clinical trial. *American Journal of Clinical Nutrition*,
2026 92:723-732. doi: 10.3945/ajcn.2010.29174

- 2027 Wollgast J, Storcksdieck genannt Bonsmann S, Tan M, Meusel V, Grammatikaki E and Bakogianni I,
2028 2018. Food-Based Dietary Guidelines in Europe. European Commission, Joint Research Centre (JRC),
2029 available online: [https://knowledge4policy.ec.europa.eu/health-promotion-knowledge-gateway/
2030 topic/food-based-dietary-guidelines-europe_en](https://knowledge4policy.ec.europa.eu/health-promotion-knowledge-gateway/topic/food-based-dietary-guidelines-europe_en)
- 2031 Wood JD, Enser M, Richardson RI and Whittington FM, 2007. Fatty acids in meat and meat products.
2032 In: Chow CK (ed.). Fatty acids in foods and their health implications. Boca Raton, FL, USA, CRC
2033 Press. pp. 87-107.
- 2034 World Cancer Research Fund and American Institute for Cancer Research, 2018. Body fatness and
2035 weight gain and the risk of cancer. Continuous Project Update Report 2018, 142 pp, available online:
2036 <https://www.wcrf.org/diet-and-cancer/>
- 2037 Yao B, Fang H, Xu W, Yan Y, Xu H, Liu Y, Mo M, Zhang H and Zhao Y, 2014. Dietary fiber intake and
2038 risk of type 2 diabetes: a dose-response analysis of prospective studies. European Journal of
2039 Epidemiology, 29:79-88. doi: 10.1007/s10654-013-9876-x
- 2040 Yao P, Bennett D, Mafham M, Lin X, Chen Z, Armitage J and Clarke R, 2019. Vitamin D and calcium for
2041 the prevention of fracture: A systematic review and meta-analysis. JAMA Network Open,
2042 2:e1917789-e1917789. doi: 10.1001/jamanetworkopen.2019.17789
- 2043 Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, Toplak H and the Obesity Management
2044 Task Force of the European Association for the Study of Obesity, 2015. European Guidelines for
2045 obesity management in adults. Obesity Facts, 8:402-424. doi: 10.1159/000442721
- 2046 Zeraatkar D, Han MA, Guyatt GH, Vernooij RWM, El Dib R, Cheung K, Milio K, Zworth M, Bartoszko JJ,
2047 Valli C, Rabassa M, Lee Y, Zajac J, Prokop-Dorner A, Lo C, Bala MM, Alonso-Coello P, Hanna SE and
2048 Johnston BC, 2019. Red and processed meat consumption and risk for all-cause mortality and
2049 cardiometabolic outcomes: A systematic review and meta-analysis of cohort studies. Annals of
2050 Internal Medicine, 171:703-710. doi: 10.7326/m19-0655
- 2051 Zhang B, Xiong K, Cai J and Ma A, 2020. Fish consumption and coronary heart disease: A meta-analysis.
2052 Nutrients, 12. doi: 10.3390/nu12082278
- 2053 Zhang Y, YOU D, LU N, Duan D, Feng X, Astell-Burt T, ZHU P, HAN L, Duan S and ZOU Z, 2018. Potatoes
2054 consumption and risk of type 2 diabetes: A meta-analysis. Iranian Journal of Public Health, 47:1627-
2055 1635
- 2056 Zhang Z, Xu G, Liu D, Zhu W, Fan X and Liu X, 2013. Dietary fiber consumption and risk of stroke.
2057 European Journal of Epidemiology, 28:119-130. doi: 10.1007/s10654-013-9783-1
- 2058 Zheng J, Huang T, Yu Y, Hu X, Yang B and Li D, 2012. Fish consumption and CHD mortality: an updated
2059 meta-analysis of seventeen cohort studies. Public Health Nutrition, 15:725-737. doi:
2060 10.1017/S1368980011002254
- 2061 Zhu Y, Bo Y and Liu Y, 2019. Dietary total fat, fatty acids intake, and risk of cardiovascular disease: A
2062 dose-response meta-analysis of cohort studies. Lipids in Health and Disease, 18. doi:
2063 10.1186/s12944-019-1035-2
- 2064 Zong G, Gao A, Hu FB and Sun Q, 2016. Whole grain intake and mortality from all causes, cardiovascular
2065 disease, and cancer: A meta-analysis of prospective cohort studies. Circulation, 133:2370-2380. doi:
2066 10.1161/circulationaha.115.021101
- 2067

2068 **Appendices****Appendix A - Protocol for the provision of scientific advice on the development of harmonised mandatory front-of-pack nutrition labelling and the setting of nutrient profiles for restricting nutrition and health claims on foods (endorsed by the NDA Panel on 8 April 2021)**2069 **1. Problem formulation (assessment questions and sub-questions)**

2070 The mandate can be broken down in the following questions:

2071 1. Which nutrients and/or foods, including non-nutrient components of food (e.g. energy, dietary fibre),
2072 are of public health importance for European populations? These include:

2073 a) Nutrients and/or foods that might be consumed in excess, and

2074 b) Nutrients and/or foods for which intakes might be inadequate

2075 in the context of dietary recommendations for healthy diets of European countries or of independent
2076 scientific bodies.2077 2. Which food groups (and specific food products thereof) have important dietary roles in European
2078 populations (and subgroups thereof) owing to their nutrient composition and frequency of intake?2079 3. Which criteria should be considered when selecting the nutrient and non-nutrient components of
2080 food for nutrient profiling?2081 **2. Definition of evidence needs based on the sub-question formulation**

2082 To address question 1:

2083 a) Identification of diet-related chronic diseases which were considered in the setting of FBDGs
2084 by Member States;2085 b) Evidence on the relationship between nutrients, non-nutrient components (e.g. energy, dietary
2086 fibre), foods and food groups, and the diet-related chronic diseases identified under point (a);2087 c) Selection of nutrients, non-nutrient components, foods and food groups, identified under point
2088 (b), which are considered of public health importance by one or more Member States.

2089 To address question 2:

2090 a) Information on main food groups and specific food products thereof with important dietary
2091 roles in European populations (and subgroups thereof) as recognised by Member States in
2092 FBDGs.

2093 To address question 3:

2094 a) Information on existing nutrient profiling models;

2095 b) Evidence from questions 1 and 2 above.

2096 **3. Identification of the adequate sources of information/data**2097 Owing to the wide scope of this mandate and the stringent deadline, the Panel will consider review
2098 publications and EFSA Scientific Opinions as the main sources of information and data. In particular,
2099 the Panel will consider:2100 a) Responses to a questionnaire sent to EU/EEA countries through EFSA focal points with the aim
2101 of gathering information on the diet-related chronic diseases which formed the basis of setting
2102 of FBDGs and on the nutrients, non-nutrient components, foods and food groups considered
2103 of public health importance;2104 b) Review publications on nutritionally adequate diets based on evidence from intervention and
2105 observational studies in humans (e.g. WHO (2003), Willett et al. (2019));

- 2106 c) Data from the Global Burden of Disease framework³⁵;
- 2107 d) Clinical practice guidelines
- 2108 e) FBDGs in Europe³⁶;
- 2109 f) EFSA Scientific Opinions on Dietary Reference Values for energy, water, macro- and
2110 micronutrients;
- 2111 g) EFSA Scientific Opinions on health claims made on food;
- 2112 h) Other EFSA Scientific Opinions on the relationship between nutrients and/or foods/food groups
2113 and human health, e.g. health benefits of seafood (fish and shellfish) consumption (EFSA NDA
2114 Panel, 2014c);
- 2115 i) EFSA Scientific Opinions on nutrient profiles to limit health claims on foods (EFSA, 2008) and
2116 on the development of FBDGs (EFSA NDA Panel, 2010d);
- 2117 j) Comprehensive review on front-of-pack labelling schemes provided by the European
2118 Commission³⁷.

2119 **4. Method for data extraction from included studies**

2120 No data extraction is foreseen.

2121 **5. Method for appraising evidence**

2122 Appraisal of included studies is not foreseen.

2123 **6. Preliminary identification of sources of uncertainty**

- 2124 • The assessment will be based on review publications and not on primary studies;
- 2125 • The classification of foods into food groups may not be well defined and/or differ across sources
2126 of information and data;
- 2127 • Information on the relationship between the intake of nutrients, non-nutrient components of
2128 food, foods and food groups and diet-related disease endpoints may only be available from
2129 human observational studies;

2130 **7. Methods for analysing uncertainties individually and combined**

2131 Uncertainties will be identified and documented at each step of the assessment, but no formal
2132 uncertainty assessment is foreseen.

2133 **8. Methods for synthesising evidence**

2134 The method for synthesising the evidence will be appropriate to the evidence retrieved.

2135

³⁵ <http://www.healthdata.org/diet>; <https://www.thelancet.com/gbd> ; <https://vizhub.healthdata.org/gbd-compare/#>

³⁶ [https://ec.europa.eu/jrc/en/health-knowledge-gateway/promotion-prevention/nutrition/food-based-dietary-guidelines#:~:text=Food%2DBased%20Dietary%20Guidelines%20\(FBDGs,acceptable%20and%20practical%20to%20imple ment](https://ec.europa.eu/jrc/en/health-knowledge-gateway/promotion-prevention/nutrition/food-based-dietary-guidelines#:~:text=Food%2DBased%20Dietary%20Guidelines%20(FBDGs,acceptable%20and%20practical%20to%20imple ment)

³⁷ <https://ec.europa.eu/jrc/en/publication/eur-scientific-and-technical-research-reports/front-pack-nutrition-labelling-schemes-comprehensive-review>

Appendix B – Survey in EU/EEA Member States on diet-related chronic diseases considered in national Food Based Dietary Guidelines (FBDGs)

2136 The survey had the following contents:

2137

2138 NAME*:

2139 COUNTRY*:

2140 AFFILIATION*:

2141 EMAIL*:

2142 DATE:

2143

2144 We kindly ask you to fill the survey. Please answer to the questions by ticking the relevant boxes and
2145 specify where relevant.

2146

2147 **1. Does your country have FBDG?**

2148

2149 **No**

2150 **Yes**

2151 **If yes, please specify the year in which your national FBDGs were last updated (or**
2152 **developed, if only one version exist):** _____

2153

2154 **2. Was the risk of diet-related chronic diseases considered when developing/ updating**
2155 **your FBDGs?**

2156

2157 **No**

2158 **Yes**

2159 **If yes, please specify the diet-related chronic diseases that were considered when**
2160 **developing/ updating your national FBDGs:** _____

2161 a. Cardiovascular diseases:

2162 b. Dyslipidemia:

2163 c. Hypertension:

2164 d. Type 2 diabetes:

2165 e. Overweight/obesity:

2166 f. Osteoporosis/bone fractures:

2167 g. Iron deficiency anaemia:

2168 h. Iodine deficiency disorders:

2169 i. Dental caries:

2170 j. Others: Please specify _____

2171

2172

2173 **3. Have you identified at national level nutrients for which intakes may be inadequate**
2174 **for the whole population or subgroups thereof?**

2175

2176 **No**

2177 **Yes**

2178 **If yes, please specify the nutrients and population groups to which this applies:**

2179 _____

2180

2181 **4. Do you have a national programme of vitamin/mineral supplementation or**
 2182 **fortification in place in your country? (e.g. iodine in salt, vitamin D supplements for**
 2183 **specific population groups, folate for women willing to become pregnant, etc)**
 2184

2185 **No**

2186 **Yes**

2187 **If yes, please specify:** _____

2188

2189 Twenty-four European countries replied to the surveys with the following results:

Q		NO		YES	Specify	
1.	Does your country have FBDGs?	2x		22x	2002-2021	
2.	Was the risk of diet-related chronic diseases considered when developing/ updating your FBDGs?			22x		
a.	Cardiovascular diseases:			21x		
b.	Dyslipidemia:			20x		
c.	Hypertension:			19x		
d.	Type 2 diabetes:			21x		
e.	Overweight/obesity:			20x		
f.	Osteoporosis/bone fractures:			18x		
g.	Iron deficiency anaemia:			15x		
h.	Iodine deficiency disorders:			16x		
i.	Dental caries:			15x		
j.	Others: Please specify					
					<ul style="list-style-type: none"> ■ Cancer (14x), ■ Mental health / Neurodegenerative/ Neurocognitive disorders (e.g. Alzheimer's disease, dementia, depression and anxiety disorder) (5x) ■ Chronic obstructive pulmonary disease (2x), ■ Musculoskeletal diseases (the mediators of which are overweight and obesity) (1x) ■ Arthrosis (1x) ■ Liver cirrhosis (1x) ■ Chronic kidney disease (1x) ■ Digestive tract diseases (1x) ■ Protein deficiency (1x) 	

		<ul style="list-style-type: none"> ▪ Gallbladder and biliary tract diseases (1x) ▪ Immune disorders (1x) ▪ Risk of infectious diseases (1x) ▪ Other conditions (e.g. constipation, dehydration) (1x) ▪ Prevent of birth defects (NTDs) through folic acid in women of child-bearing age (1x) ▪ Other diseases and early total mortality (1) 				
3.	Have you identified at national level nutrients for which intakes may be inadequate for the whole population or subgroups thereof?	2x		22x		
		<ul style="list-style-type: none"> ▪ Vitamin D (17 countries^(a): 13x general population^(b), 6x children, 1x pregnant women, 4x elderly) ▪ Iodine (13 countries: 6x general population, 3x women, 2x pregnant women, 1x lactating women) ▪ Folate (12 countries: 3x general population, 2x adults, 2x children, 3x women, 3x pregnant women, 1x adolescents, 1x elderly) ▪ Calcium (8 countries: 5x general population, 1x girls, 1x elderly, 1x women, 1x adults) ▪ Iron (8 countries: 1x general population, 6x children, 1x women, 3x pregnant women, 1x elderly) ▪ Dietary fibre (7 countries: 5x general population, 1x children, 2x adults) ▪ Zinc (4 countries: 1x general population, 2x children, 1x pregnant women, 1x women, 2x elderly) ▪ Selenium (4 countries: 2x general population, 2x elderly, 1x women) ▪ Vitamin C (4 countries: 2x general population, 2x elderly) ▪ Potassium (4 countries: 2x general population, 1x elderly and older women, 1x children) ▪ Vitamin B6 (3 countries: 1x general population, 2x elderly) ▪ Magnesium (3 countries: 3x general population) ▪ Omega 3 fatty acids/ DHA / EPA (3 countries; 2x general population, 1x children, 1x adults) ▪ Vitamin B12 (3 countries: 1x general population, 1x elderly, 1x vegans) ▪ Vitamin A (2 countries: 1x general population, 1x children, 1x pregnant women, 1x elderly) ▪ Copper (2 countries: 2x general population) ▪ Protein (2 countries: 1x general population, 1x elderly) ▪ Riboflavin (2 countries: 1x general population, 1x elderly) ▪ Phosphorus (1 country: 1x general population) ▪ Thiamin (1 country: 1x general population) ▪ Chromium (1 country: 1x general population) ▪ Niacin (1 country: 1x general population) ▪ Vitamin K (1 country: 1x general population) 				

		<ul style="list-style-type: none"> Carbohydrates (1 country: pregnant women and adults, in particular elderly) 			
4.	Do you have a national programme of vitamin/mineral supplementation or fortification in place in your country? (e.g. iodine in salt, vitamin D supplements for specific population groups, folate for women willing to become pregnant, etc)	3 x		21 x	
		<ul style="list-style-type: none"> Iodine (16 countries: salt, supplements for pregnant women, fortification of cattle) Vitamin D (15 countries: supplements for infants and young children, pregnant women, older adults, elderly, fortification of margarines, cooking oils, dairy) Folate (13 countries: supplements for women of childbearing age, pregnant women) Vitamin B12 (3 countries: supplements for vegans and the elderly) Vitamin A (2 countries fortification of margarines and cooking oils) Selenium (1 country: addition to agricultural fertilisers) Fluoride (1 country: salt, supplements for infants) Iron (1 country: supplements for pregnant women) DHA (1 country: supplements for pregnant women) Vitamin E (1 country: fortification of margarines and cooking oils) 			

2190

(a) Multiple answers possible with respect to subpopulations at risk of inadequacy

2191

(b) Responses in which no sub-population was specified have been considered under the category 'general population'

2192

2193 **Glossary and/or abbreviations and/or acronyms**

AICR	American Institute for Cancer research
ALA	α -linolenic acid
AI	Adequate Intake
ARA	arachidonic acid
AR	Average Requirement
BMD	bone mineral density
BMI	body mass index
CDC	Centers for Disease Control
CDRR	Chronic Disease Risk Reduction Intake
CHD	coronary heart disease
CVD	cardiovascular diseases
DHA	docosahexaenoic acid
DNA	deoxyribonucleic acid
DRV	Dietary Reference Value
E%	percentage of total energy intake
EC	European Commission
EEA	European Economic Area
EFSA	European Food safety Authority
EPA	eicosapentaenoic acid
EPIC	European Prospective Investigation into Cancer and Nutrition
ESPGHAN	European Society for Paediatric Gastroenterology, Hepatology, and Nutrition
EU	European Union
FBDG	food based dietary guideline
FOP	front-of-pack
GBD	Global Burden of Disease
HDL	high-density lipoprotein
IARC	International Agency for Research on Cancer
IDA	iron deficiency anaemia
IOTF	International Obesity Task Force
JRC	Joint Research Centre
LA	linoleic acid
LC	long-chain
LDL	low-density lipoprotein
MUFA	monounsaturated fatty acid
n-3	omega 3
n-6	omega 6
NCD	non-communicable disease

NDA	Panel on Nutrition, Novel Foods and Food Allergens
PRI	Population Reference Intake
PUFA	polyunsaturated fatty acid
RCT	randomised controlled trial
RI	Reference Intake range for macronutrients
RNA	ribonucleic acid
SFA	saturated fatty acid
T2DM	type 2 diabetes mellitus
TFA	<i>trans</i> -fatty acid
UIC	urinary iodine concentration
UL	Tolerable Upper Intake Level
WCRF	World Cancer Research Fund
WHO	World Health Organization

2194

DRAFT